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ABSTRACT 
 
R-SPONDIN-2 MODULATES OSTEOBLASTOGENESIS AND BONE ACCRUAL THROUGH 
WNT SIGNALING 
Meghan Noelle Knight 
Jaimo Ahn 
Kurt D. Hankenson 
The R-spondin family of proteins are Wnt agonists, and the complete embryonic disruption of 
Rspo2 results in skeletal developmental defects that recapitulate the phenotype observed with 
Lrp5/6 deficiency. Previous work has shown that Rspo2 is both highly expressed in Wnt-
stimulated pre-osteoblasts and that its over-expression induces osteoblast differentiation in the 
same cells, supporting its role as a positive autocrine regulator of osteoblastogenesis. However, 
the role of Rspo2 in the autocrine regulation of osteoblastogenesis in postnatal bone is under 
explored. Here, we show that limb-bud progenitor cells from Rspo2 knockout mice undergo 
reduced mineralization during osteoblastogenesis in vitro, and have a corresponding alteration 
in their osteogenic gene expression profile. The first Rspo2 conditional knockout (Rspo2floxed) 
mouse was generated, and Rspo2 was knocked out in osteoblasts by crossing to the Osteocalcin-
Cre mouse line (Ocn-Cre+ Rspo2f/f) to address the autocrine role of Rspo2 in vivo. Ocn-
Cre+Rspo2f/f male and female mice at 1, 3, and 6 months were examined.  Ocn-Cre+Rspo2f/f 
mice are decreased in overall body size compared to their littermates, and they have decreased 
trabecular bone mass due primarily to decreased trabecular thickness. Histomorphometric 
analysis revealed a similar number of osteoblasts and mineralizing surface per bone surface with 
a simultaneous decrease in mineral apposition and bone formation rates, suggesting that a 
decreased mineralization capacity rather than an overall reduced number of osteoblasts is the 
etiology of the reduced bone volume. In following with this, BM-MSC from Ocn-Cre+Rspo2f/f 
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mice undergo less mineralization in vitro. Overall, Rspo2 loss reduces osteoblastogenesis and 
mineralization both in vitro and in vivo, leading to reduced bone mass. 
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CHAPTER 1: INTRODUCTION  
A portion of this introduction and Figures 1.1 and 1.2 were published in a review in the journal 
Matrix Biology (Knight and Hankenson 2014) 
1.1 Clinical Significance of Bone Mass Regulation 
Bone possesses an incredible ability to repair and rebuild itself via continuous remodeling 
throughout an individual’s life. This remodeling is not only necessary for repair, but is also 
essential to maintain the integrity of the skeleton. Imbalance of the remodeling process can lead 
to either too much or too little bone tissue, leading to conditions of low and high bone mass. For 
instance, osteoporosis is a condition characterized by low bone mass, micro-architectural 
deterioration of bone tissue, and increased risk of fracture (Kanis, 1994; Kanis et al., 1994). It 
affects more than 200 million people worldwide, and the incidence is continually rising with the 
increasing life expectancies of populations across the globe. The prevalence of overall low bone 
mass is even greater. Fractures, particularly of the hip, resulting from osteoporosis are a major 
cause of morbidity, disability, and premature mortality in older individuals, creating a huge 
economic burden (Johnell and Kanis, 2006; Dhanwal et al., 2011). In the United States alone, the 
financial burden of the more than 2 million osteoporosis-related fractures per year is estimated 
at US $19 billion (Burge et al., 2007). Women account for a larger proportion of both individuals 
affected by osteoporosis and those with osteoporosis-related fractures, due to the increased 
incidence of bone loss associated with menopause. This increased bone loss results in 
approximately 30% of postmenopausal women in the United States and Europe developing 
clinical osteoporosis. At least 40% of these women will sustain one or more fragility fractures 
during the remainder of their lifetime (Kanis, 2002).  
 While osteoporosis and low bone mass occur commonly in individuals of advanced age 
secondary to menopause and age-related bone loss, they also occur in cases of disuse, in certain 
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genetic and metabolic conditions, and treatment with specific medications. Disuse most 
commonly results from prolonged bed rest, spinal cord injuries and strokes that lead to paresis 
and paralysis, and immobilization due to an injury, such as casting. Less commonly, but no less 
importantly, low bone mass occurs rapidly in low-gravity environments (Bloomfield, 2010). 
Numerous genetic conditions lead to conditions of low bone mass, such as osteogenesis 
imperfecta and osteoporosis pseudoglioma syndrome (Karasik et al., 2016). Metabolic 
disruptions such as hyperadrenocorticism and hyperthyroidism, can also result in loss of bone 
mass (Fitzpatrick, 2002; Tuchendler and Bolanowski, 2014). Similarly, medications such as 
corticosteroids and heparin are also associated with reduced bone mass with long term use 
(Panday et al., 2014). Overall, there are many clinical conditions that lead to bone loss. 
Conversely, dysregulation of bone remodeling can also lead to high bone mass. This is seen 
in several rare genetic conditions such as Sclerostosis, Van Buchem disease, and with Lrp5/6 
gain-of-function mutations (Brunkow et al., 2001; Balemans et al., 2002; Boyden et al., 2002). 
These conditions can be clinically significant, with progressive bone growth leading to 
impingement of the cranial nerves due to stenotic foramina of the skull and subsequent 
auditory loss, visual loss, anosmia, increased intracranial pressure, and facial palsies. 
Malformations including syndactyly and mandibular hypertrophy are common in the more 
severe condition of Sclerostosis. Though there are only a few recognized clinical conditions of 
high bone mass to date, many mutations can lead to subclinical increases in bone mass, with 
reported resistance to fracture in high impact trauma and anecdotal reports of decreased 
buoyancy in water (Gregson et al., 2012). GWAS studies have further identified many loci that 
contribute negatively or positively to overall bone mass in both monogenetic and polygenetic 
manners, suggesting that there is still much to be investigated regarding normal variations and 
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subclinical changes in bone mass and how this relates to the clinical burden of fractures and 
osteoporosis (Karasik et al., 2016). Moreover, much like the reciprocal case for decreased bone 
mass, several metabolic conditions and medications, such as hypothyroidism and lithium 
chloride, can cause increases in bone mass. 
The current therapeutics designed for osteoporosis treatment and prevention are limited in 
their scope and clinical effectiveness. The most commonly prescribed agents are the anti-
resorptive bisphosphonates. While these are effective at preventing resorption, they do not 
promote increased bone production to further restore bone already lost. Denosumab is an 
antibody-mediated therapeutic targeted at RANK-Ligand (RANKL), that also functions through 
inhibition of bone resorption (Cummings et al., 2009). Teriparatide is a recombinant peptide 
drug based on parathyroid hormone and was the first anabolic agent approved to treat 
osteoporosis. Currently it is only labeled for those at high risk of fracture, and the length of 
treatment is limited (Bodenner et al., 2007).  An agent related to teriparatide, abaloparatide, 
also was recently approved by the FDA (Radius Health, 2017).  A second osteoanabolic 
therapeutic, romosozumab, is on track for approval this year (Lim and Bolster, 2017). This is an 
antibody targeting Sclerostin, an antagonist of canonical Wnt signaling in bone, and has been 
successful in clinical trials thus far. While these therapeutics do increase bone mass, there are 
significant limitations in treatment options and in clinical effectiveness, particularly in the realm 
of osteoanabolics.  
It is clear that conditions of both low and high bone mass can be of considerable clinical 
significance. As will be discussed in the next section, the regulation of bone strength through 
bone mass and architecture is multifactorial and stems from a myriad of mechanisms. As a 
result, many conditions cause alterations in bone mass. Among these, osteoporosis is of 
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particularly considerable concern due to its extensive associated global morbidity, mortality, and 
economic burden, necessitating the discovery of novel therapeutics. 
 
1.2 Bone Mass Regulation 
Bone mass refers to the physical mass of bone tissue in the skeleton, with contributions 
from both the bone tissue volume as well as the density of the tissue. Together with bone 
architecture, it is the main determinant of the strength of the skeleton. In adults, bone mass is 
regulated through the precise balance and coupling of osteoclastic bone resorption and 
osteoblastic bone formation in a process known as bone remodeling. The primary functions 
underlying this process are the replacement of old or damaged bone, response to changes in 
mechanical stress, and calcium homeostasis (Harada and Rodan, 2003).  
Remodeling occurs continuously throughout an individual’s lifetime in response to 
numerous hormonal and mechanical signals, allowing the body to adapt to both metabolic and 
physical stresses. Bone remodeling begins with recruitment of bone-resorbing osteoclasts to the 
bone surface, followed by bone resorption. A reversal phase then occurs with the apoptosis of 
the osteoclasts and recruitment of bone-building osteoblasts. Finally, bone matrix deposition by 
the recruited osteoblasts replaces the resorbed bone (Figure 1.1). It is estimated that in healthy 
individuals, the adult skeleton is renewed entirely by this remodeling process every ten years 
(Manolagas, 2000).  
There are many factors that can lead to an imbalance in the bone remodeling process, which 
in turn leads to overall loss or gain of bone mass. Systemic requirements for calcium are 
mediated primarily through parathyroid hormone (PTH) and can indirectly increase osteoclast 
activity and subsequent calcium release, whereas high serum calcium levels can stimulate the 
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release of calcitonin, which directly inhibits osteoclast activity to reduce further calcium release 
(Zuo et al., 2012). PTH also induces the activation of Vitamin D, which then stimulates osteoclast 
differentiation and decreases osteoblastogenesis (Bell et al., 2010). Mechanical loading and 
unloading both have strong and opposing effects on bone remodeling, which are mediated by 
numerous cellular signals (Bloomfield, 2010). Sex steroids have a significant impact on bone 
remodeling, as can be seen with the changes in remodeling following menopause, resulting from 
decreased estrogen levels. Estrogen does this primarily by decreasing the absolute osteoclast 
number, while testosterone can either increase bone mass indirectly by conversion to estrogen 
or through a direct effect on bone formation (Manolagas, 2000).  
Beyond these metabolic influences on bone mass regulation, genetics are also incredibly 
important. Many polymorphisms and specific gene mutations have been associated with 
alterations in bone mass. GWAS analysis has revealed that many of these associated genes are i) 
part of the Wnt signaling pathway (e.g. LRP5/6, SOST, WNT3, WNT16, WTS, AXIN1, CTNNB1), ii) 
part of the hormonal signaling pathways mentioned above (e.g. Vitamin D Receptor, Estrogen 
Receptor, PTH), iii) involved in osteoblast differentiation and function (e.g. RUNX2, SP7, SMOC1), 
or iv) involved in osteoclast differentiation (e.g. TNFSF11, TNFRSF11A/B, CLCN7) (Karasik et al., 
2016). Many of these genes have also been correlated with rare mutations that cause pathologic 
conditions of low bone mass. These GWAS findings corroborate and shed light on both already 
known and potential novel cellular and signaling mechanisms of bone mass regulation. 
1.3 Osteoblastogenesis 
Osteoblasts are critical to building and maintaining bone mass, and are responsible for 
the deposition of immature bone matrix, termed osteoid, on bone surfaces. Mesenchymal 
progenitor cells, sometimes referred to as mesenchymal stem cells (MSC), differentiate to 
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osteochondral progenitors, then subsequently undergo the differentiation to pre-osteoblasts, 
osteoblasts, and ultimately osteocytes. Critical regulatory points during this process include the 
renewal of MSC, the stimulation of precursor replication, the initiation of and progression 
through osteoblastogenesis, and the inhibition of osteoblast and osteocyte apoptosis. Since 
MSC can also differentiate into chondrocytes and adipocytes, another point of regulation is the 
inhibition of other differentiation towards these fates (Zuo et al., 2012).  
The master regulator of osteogenesis is the transcription factor Runx2, and its 
expression is critical for the commitment of MSC to the osteoblast lineage. Osterix (Osx) 
expression increases following Runx2 expression, after mesenchymal condensation has 
occurred, and is a hallmark of the pre-osteoblast stages. Alkaline phosphatase (ALP), a protein 
essential for mineral metabolism in bone, is also expressed at this stage. After this, osteocalcin 
(Ocn), Type-1 Collagen (Col1), and bone sialoprotein (BSP) are expressed, marking the transition 
from pre-osteoblasts to immature osteoblasts (Bruderer et al., 2014). Osteocyte markers, such 
as Phex and Dmp1, are expressed as the osteoblasts mature into osteocytes in the bone matrix 
(Bonewald, 2011). Many cellular signaling pathways have identified roles in osteoblastogenesis, 
with Runx2 being a main point of integration for these signals. The canonical Wnt, BMP, and 
Notch signaling pathways have all been implicated as positive regulators, among others (Lin and 
Hankenson, 2011; Knight and Hankenson, 2013). Though this general sequence has been 
determined, and osteoblastogenesis can be monitored through these changes in gene 
expression, the precise control and transcriptional cascade involved in osteoblastogenesis and 
resultant effect on phenotype still need to be delineated.  
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1.4 The Wnt Signaling Pathway 
Canonical Wnt signaling, functioning through beta-catenin stabilization, is involved in a 
wide array of physiologic developmental and homeostatic functions. As mentioned above, it is 
one of the primary signaling pathways involved in osteoblastogenesis and bone accrual, making 
it of critical importance to the study of osteoporosis and bone remodeling. There are also 
numerous noncanonical, or beta-catenin-independent signaling pathways with less established 
roles in bone (Monroe et al., 2012).  
The canonical Wnt signaling pathway is activated when a Wnt ligand binds to its co-
receptors at the cell surface. The core receptors in canonical Wnt signaling are the Frizzled 
family of G-protein-coupled receptors and the low-density lipoprotein receptor-related proteins 
5 and 6 (LRP5 and LRP6). This ligand binding results in the recruitment of members of the beta-
catenin destruction complex to the cell membrane. The beta-catenin destruction complex 
contains the proteins Disheveled (Dvl), Axin2, Glycogen synthase kinase 3beta (GSK3beta), 
Casein kinase 1 alpha (CK1alpha), and Adenomatosis polyposis coli (APC). In the absence of 
bound Wnt ligand, this complex recruits and phosphorylates beta-catenin, targeting it for 
ubiquitination and subsequent destruction in the proteasome. The complex is inactivated when 
members of this complex are recruited away from this complex following Wnt ligand binding, 
and stable, non-phosphorylated cytoplasmic beta-catenin accumulates. This beta-catenin can 
then translocate to the nucleus and interact with the Tcf/Lef family of transcription factors to 
alter gene transcription. Many extracellular modulators of Wnt signaling have been discovered, 
including the dickopfs (DKK), secreted Frizzled-related proteins (sFRP), Wnt Inhibitory Factor 
(WIF), and Sclerostin (SOST) (Nusse and Clevers, 2017).  
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In contrast to the beta-catenin signaling described above, noncanonical Wnt signaling 
does not stabilize beta-catenin. There are multiple noncanonical Wnt pathways that have been 
investigated, including the Wnt/Planar Cell Polarity Pathway (PCP) and Wnt/Ca2+ Pathway. In 
bone, the noncanonical pathway with the most evidence supporting a function role is the 
Wnt/PCP pathway (Caverzasio, 2009). Similar to canonical signaling, activation of this pathway is 
initiated by ligand binding to Frizzled and a co-receptor. However, co-receptors other than 
Lrp5/Lrp6 are utilized, and downstream signaling involves the small GTPases Rho, Rac, and JNK. 
In Wnt/Ca2+ signaling, calcium is released from the endoplasmic reticulum in response to Wnt 
ligand binding. This is thought to be mediated by the Frizzled receptors’ G-protein coupling. 
Despite the often-described clear distinction between these canonical and non-canonical 
pathways, they are most likely integrated at various points along the signaling pathway. In fact, 
many of the various Wnt ligands have been shown to activate multiple Wnt signaling pathways 
depending on the context (Kobayashi et al., 2015; Kobayashi et al., 2016). 
1.5 Wnt Signaling and Bone Mass Regulation 
Canonical Wnt signaling is involved in regulation of the mature skeleton. Canonical signaling 
was first implicated in bone mass regulation in 2001, when mutations in the Wnt co-receptor 
LRP5 were found to be associated with a low bone mass phenotype in humans (Gong et al., 
2001). Corresponding gain-of-function mutations in LRP5 resulting in a high bone mass 
phenotype were identified soon after (Boyden et al., 2002; Little et al., 2002). Mutations in the 
related Wnt co-receptor LRP6 lead to similar phenotypes. Polymorphisms in both receptors have 
also been correlated with bone mass. The role of canonical Wnt signaling in bone is further 
supported by loss-of-function mutations in sclerostin, a Wnt antagonist in bone, that lead to 
Sclerosteosis and Van Buchem Disease in humans. Furthermore, there is increased bone mass 
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seen with anti-sclerostin antibody administration in animal models and humans (Ominsky et al., 
2010; Padhi et al., 2011; McClung et al., 2014).  
Many murine models involving alterations of Wnt signaling have corroborated the positive 
role of canonical Wnt signaling on bone mass. Conditional knockouts of beta-catenin (Cttnb1) 
cause severe decreases in bone mass, with earlier disruptions also leading to skeletogenesis 
defects (Glass et al., 2005; Hill et al., 2005; Hu et al., 2005). Conditional deletions specifically in 
osteoblasts result in decreases in trabecular and cortical bone mass without skeletogenesis 
defects (Holmen et al., 2005; Kramer et al., 2010). Similarly, knockouts of Lrp5 and Lrp6 lead to 
decreased bone mass, even with limited disruption by knock out only in the osteocytes via 
Dmp1-Cre (Kato et al., 2002; Fujino et al., 2003; Holmen et al., 2004; Cui et al., 2011). Lrp6 
homozygous knockout mice are perinatal lethal and have limb malformations resulting in 
missing digits (Pinson et al., 2000). When the Lrp5 and Lrp6 knockout models are bred together 
to create double knockouts, skeletogenesis defects occur with loss or reduction of digits. The 
most severely affected animals had complete loss of limbs, synostoses of carpal and tarsal 
bones, and only a single hindlimb digit (Holmen et al., 2004). Knockouts of Wnt3a or Wnt5a lead 
to reduced bone mineral density and trabecular number (Takada et al., 2007). Knockout of 
Wnt10b leads to progressive osteopenia, with decreased bone mineral density and trabecular 
number but no decrease in trabecular thickness (Bennett et al., 2005; Bennett et al., 2007; 
Stevens et al., 2010). Knockout of sclerostin and DKK, negative regulators of Wnt signaling, 
result in increased bone mass (Balemans et al., 2002; Morvan et al., 2006; Krause et al., 2010). 
While the phenotypes differ in severity, a general trend of decreased bone mass is observed 
among all disruptions of canonical Wnt signaling in bone. 
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1.6 Wnt Signaling and Osteoblastogenesis 
Canonical Wnt signaling is involved in the induction of myogenic and osteogenic 
differentiation, as well as the inhibition of chondrogenesis and adipogenesis, making it a critical 
regulator of MSC lineage commitment (Day et al., 2005; Hill et al., 2005; Hu et al., 2005; Kennell 
and MacDougald, 2005). The stabilization of beta-catenin through canonical Wnt signaling has 
been found to have significant effects throughout osteoblastogenesis. In MSC, beta-catenin 
stabilization enhances commitment to and differentiation of the osteoblast cell lineage, with 
concomitant repression of differentiation along the chondrogenic and adipogenic lineages (Day 
et al., 2005; Hill et al., 2005; Hu et al., 2005; Kennell and MacDougald, 2005; Bennett et al., 
2007; Miclea et al., 2009). Furthermore, proliferation and survival of osteoblasts is modulated 
by canonical Wnt signaling (Monroe et al., 2012). Osteoblasts and osteocytes also modulate 
osteoblast-osteoclast coupling in response to stabilized beta-catenin by producing 
osteoprotegerin, which inhibits osteoclasts (Glass et al., 2005). The data concerning the effects 
of Wnt signaling on osteoblasts have been corroborated by a large array of mouse models, 
demonstrating increased bone mass with increased beta-catenin stabilization in osteoblastic 
lineage cells, and reduced bone mass with decreased canonical signaling (Holmen et al., 2004; 
Hill et al., 2005; Holmen et al., 2005; Kugimiya et al., 2007; Cui et al., 2011; Wei et al., 2011). 
1.7 R-spondins  
The R-spondins, a family of four secreted proteins in the thrombospondin type 1 repeat 
(TSR1)-containing protein superfamily, are well recognized Wnt signaling agonists. Homologues 
of R-spondins are present in all vertebrates as well as select invertebrates, such as 
hemichordates, chordates, and echinoderms, but not Drosophila and Caenorhabditis 
elegans (Cruciat and Niehrs, 2013). In mammals, R-spondins have ~ 60% sequence homology, 
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and all R-spondins have a similar modular domain structure: an N-terminal putative signal 
sequence for secretion, two sequential cysteine-rich furin-like domains, a single TSR1, and a 
positively charged C-terminus (Hankenson et al., 2010; de Lau et al., 2012) (Fig. 1). The TSR1 
domain contains conserved tryptophans and a conserved cysteine-rich CSVTCG domain, with the 
valine and threonine residues variably replaced with amine-containing side-group residues in 
different TSR1-domain-containing proteins. Specifically, each R-spondin has the VT residues 
replaced with two basic amino acids (either lysine or arginine), one or two polar amino acids 
(e.g. glutamine, asparagine) or in the case of Rspo3 and Rspo4, a single glycine. 
Though Rspo3 was originally identified in 1971, as ‘thrombin-sensitive protein’ (Baenziger et 
al., 1971), the R-spondin family only began to be elucidated in 2002, with the discovery of Rspo1 
(Chen et al., 2002) and subsequent discovery and characterization of the remaining members 
(Kamata et al., 2004; Kazanskaya et al., 2004; Kim et al., 2006). R-spondins are likely bound to 
heparan-sulfated proteoglycans in the extracellular matrix (ECM), as evidenced by their near 
lack of detection in the medium of transfected cells, their subsequent release with added 
soluble heparin, and their binding to Syndecan 4 (Nam et al., 2006; Ohkawara et al., 2011). 
However, potential interactions with other ECM molecules are not well-described. 
The four R-spondin family members can potently activate canonical Wnt signaling in a 
Wnt-dependent manner, and their furin-like domains are necessary and sufficient for this 
activity (Kazanskaya et al., 2004; Nam et al., 2006; Kim et al., 2008; Glinka et al., 2011). The 
mechanism, and more specifically the receptor, for this activation has been highly debated for 
several years, with reports of Frizzled 8, low-density lipoprotein receptor-related protein 6 
(LRP6), and Kremen all binding to R-spondins. However, none of these studies have been 
confirmed (Nam et al., 2006; Binnerts et al., 2007; Wei et al., 2007; Glinka et al., 2011; 
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Ohkawara et al., 2011). In 2013, the furin domain of the R-spondins was found to bind to 
leucine-rich repeat-containing G-protein-coupled receptors 4-6 (LGR4-6) (Chen et al., 2013) after 
several studies identified these as receptors for the R-spondins with a Kd in the nanomolar range 
(Carmon et al., 2011; de Lau et al., 2011; Glinka et al., 2011; Ruffner et al., 2012). The current 
proposed mechanism for the R-spondin-mediated activation of canonical Wnt signaling is the 
formation of a ternary complex of LGR, R-spondin, and the transmembrane RING-type E3 
ubiquitin ligase ZNRF3 or RNF43 (Hao et al., 2012; Koo et al., 2012), which thereby alleviates 
ZNRF3/RNF43 membrane clearance of the Frizzled–LRP Wnt coreceptor complex (Hao et al., 
2012) (Fig. 2). R-spondins can also enhance non-canonical Wnt/PCP signaling through the TSR1 
domain during Xenopus development (Ohkawara et al., 2011). The ability of R-spondins to bind 
to structural extracellular matrix proteins, such as heparan-sulfated proteoglycans, along with 
their ability to bind cell surface receptors and potentiate Wnt signaling, clearly defines R-
spondins as matricellular proteins. 
 
R-spondin family member functions 
Rspo1 
The most prominent phenotype related to R-spondin 1 dysfunction is due to its role in gonadal 
development, with mutation leading to a rare form of XX male sex reversal (Parma et al., 2006). 
Rspo1 is expressed in the developing ovary, neural tube, kidney, stomach, dermis, mammary 
glands, limb bud, long bones, craniofacial bones, and vertebrae in the mouse (Nam et al., 2007b; 
Tomizuka et al., 2008). Rspo1-null mice have decreased fertility and lack duct branching and 
alveolar formation in the mammary glands, leading to a failure of lactation (Chadi et al., 2009). 
Systemic administration of Rspo1 in mice leads to a dramatic enlargement of the 
gastrointestinal tract with extensive proliferation of the crypt epithelial cells (Kim et al., 2005). 
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Rspo2 
The major phenotypes associated with the global loss of R-spondin 2 during development are 
limb and craniofacial malformations and hypomorphic lungs due to defective branching, which 
result in perinatal death (Bell et al., 2008; Yamada et al., 2009). Rspo2-null mice also exhibit 
laryngeal–tracheal and kidney malformation. During development, Rspo2 is prominently 
expressed in the apical ectodermal ridge (AER) of the limb bud, and additional expression has 
been seen in the developing lungs, brain, pharynx, teeth, long bones, craniofacial bones, and 
vertebrae (Nam et al., 2007b). Rspo2 morpholinos injected into Xenopus embryos inhibited the 
expression of myogenic markers, suggesting a role for Rspo2 in myogenesis (Kazanskaya et al., 
2004). Additionally, a 3′UTR insertion in the Rspo2 gene in dogs that increases the mRNA 
stability causes increased hair growth on the face and legs (Cadieu et al., 2009; Parker et al., 
2010). Loss of Rspo2 reduces Wnt signaling activity in the area of expression, and genetic 
epistasis was observed when the skeletal phenotype of Rspo2 null mice was exacerbated by 
crossing to an Lrp6 knockout line, suggesting that the main mechanism of Rspo2 function is 
through the canonical Wnt pathway (Bell et al., 2008). 
Rspo3 
R-spondin 3 deficiency during development leads to vascular defects in the placenta of mice, 
with no penetration of fetal blood vessels into the chorion due to a lack of induction of VEGF 
expression in the placenta (Aoki et al., 2007; Kazanskaya et al., 2008). Rspo3 is highly expressed 
in the primitive streak during very early development and is also expressed in the developing 
neural tube, brain, limb bud, heart, kidney, and small intestine. However, embryonic death 
around embryonic day 10 (E10) limits the detection of further effects of Rspo3 deficiency (Nam 
et al., 2007b). Kazanskaya et al. describe a shift from blood cell specification to angioblast 
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specification with the addition of Rspo3 in vitro (Kazanskaya et al., 2008). Rspo3 is thought to be 
partially redundant with Rspo2 in hindlimb development due to observed increases in severity 
of defects in double mutant mice despite no observed effects of Rspo3 knockout alone in the 
limb bud mesenchyme (Neufeld et al., 2012). 
Rspo4 
The prominent feature of R-spondin 4 loss is anonychia, the absence of nails. Rspo4 is only 
weakly expressed in the developing neural tube, but there is much higher expression in the 
developing heart and limb buds (Bergmann et al., 2006; Nam et al., 2007b). Expression in the 
claw primordia in the mouse can also be detected (Bergmann et al., 2006). Mutations in Rspo4 
that led to isolated anonychia are clustered in the two cysteine-rich furin-like domains, which 
are known to be important in the potentiation of canonical Wnt signaling by R-spondins (Brüchle 
et al., 2008). 
 
1.8 R-spondins and Bone 
R-spondins have recently been recognized as modulators of the skeleton. During 
development, all four R-spondins are expressed in the developing limb bud. Rspo1 has weak 
expression in the ectoderm and mesoderm at the junction of the limb bud and the trunk at 
embryonic stage 10.5 (E10.5). Much stronger expression is seen in the mesenchyme of the 
developing phalanges between E12.5 and E14.5. Robust Rspo2 expression in the limb bud is 
associated with the AER between E10.5 and E14.5 (Bell et al., 2003; Nam et al., 2007a). Rspo2 
knockout mice are the only Rspo knockouts with a described skeletal phenotype, with loss of the 
autopod and fibula on the hindlimbs, loss of digits and some radii on the forelimbs, and the 
complete absence of nails coincident with the loss of the distal phalanx on all formed digits. 
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Cleft palates and craniofacial malformations have also been noted. This phenotype is consistent 
with a reduction in Wnt signaling as demonstrated in a variety of mouse models of disrupted 
Wnt signaling (Gong et al., 2001). Interestingly, this phenotype is more severe in the left 
hindlimb and the right forelimb (Bell et al., 2003). Double Rspo2/Rspo3 null mice have a more 
severe phenotype, suggesting at least partial redundancy despite a lack of skeletal phenotype in 
Rspo3 null mice alone (Neufeld et al., 2012). Rspo3 is expressed in the mesenchymal cells of the 
limb bud (between the expression of Rspo2 and Rspo4) at E10.5 and extends into the 
interdigitary spaces and nail primordia at E12.5 and E14.5, respectively. Rspo4 is expressed in 
the zone of polarizing activity, the anterior limb bud, and the most distal tips of the digits. These 
data suggest that Rspo2 and Rspo3 play a significant role in the maintenance of the AER and 
thus elongation of the limb bud and formation of distal structures. All R-spondins appear to play 
a role in the development of the most distal phalanges and nails. Additionally, all four R-
spondins have some expression in the craniofacial bones and Rspo2 deletion results in 
malformation, suggesting a role for R-spondins in the development of these intramembranous 
bones (Nam et al., 2007a; Hankenson et al., 2010). 
Current research supports a role for R-spondins in the mature skeleton, though studies are 
limited. Rspo1 synergizes with Wnt3A in C2C12 cells and primary murine calvarial cells in vitro, 
leading to increased osteoblastic differentiation (as measured by ALP activity and osteocalcin 
expression) and osteoprotegerin expression (Lu et al., 2008). Similarly, Rspo2 overexpression 
enhances MC3T3E1 osteoblastic differentiation (as measured by ALP activity, mineral staining, 
and gene expression) in the presence of BMP, and Rspo2 knockdown abrogates the enhanced 
differentiation seen with Wnt11 overexpression (Friedman et al., 2009). Rspo1 transcript levels 
increase in human primary osteoblasts and FOB1.19 cells during differentiation, and 
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recombinant Rspo1 administration can increase both beta-catenin stabilization and ALP activity 
in vitro (Sharma et al., 2013). Rspo1 levels also increased in response to vibration in vitro, and 
systemic administration of recombinant Rspo1 increased both mineral apposition rate and bone 
volume in three mouse models of aging known to have osteoporotic phenotypes (Wang et al., 
2013). Deletion of the R-spondin receptor LGR4 in mice results in reduced bone mass due to 
both decreased bone formation and increased bone resorption, suggesting a role for R-spondins 
in mature bone maintenance (Luo et al., 2009). From a therapeutic perspective, recombinant 
Rspo1 injected into the joints of a murine arthritis model (TNFα overexpression — TNFtg) 
inhibited osteoclast development while stimulating osteoblast development, thus decreasing 
bone erosion and increasing cartilage integrity (Krönke et al., 2010). Furthermore, Rspo2 mRNA 
and protein expression is decreased in osteoarthritis (OA) patients. Rspo2 siRNA decreased 
mineralization of osteoblasts from healthy patients, and recombinant Rspo2 was able to 
increase the mineralization of osteoblasts from patients with osteoarthritis. Beta-catenin 
stabilization is also decreased in cells derived from OA patients, and recombinant Rspo2 is able 
to restore this stabilization to physiologic levels (Abed et al., 2011). Though many studies remain 
to be done, the R-spondin family provides a promising target for osteoanabolic therapeutics. 
R-spondins are characterized as matricellular proteins on the basis of their expression in a 
variety of mesenchymal derived tissues, particularly the skeleton, and their ability to interact 
with both the extracellular matrix and a variety of cellular receptors. In the skeleton, R-spondins 
clearly have pro-osteoblastic effects; additionally, Rspo2 and perhaps Rspo3 regulate the 
process of endochondral ossification. R-spondins regulate Wnt/beta-catenin signaling, and the 
effects of R-spondins on osteoblasts and limb development are consistent with a reduction in 
beta-catenin stabilization and subsequent signaling. A number of questions remain concerning 
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the role of R-spondins in the skeleton, including the functional redundancy of the family 
members, demonstrating the signaling mechanisms of R-spondins in skeletal cells, and 
understanding the regulation of R-spondin expression and activity during skeletogenesis, the 
maintenance of adult bone mass, and bone healing. 
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Figure 1.1. Bone remodeling. 1. Bone remodeling begins with the activation and recruitment of 
bone-resorbing osteoclasts (purple) to the bone surface. 2. This is followed by osteoclastic bone 
resorption. 3. A reversal phase then occurs with the apoptosis of the osteoclasts and 
recruitment of bone-building osteoblasts (orange). 4. Finally, bone matrix deposition by the 
recruited osteoblasts replaces the resorbed bone. Osteocytes (blue) are terminally 
differentiated osteoblasts that have become surrounded by the newly formed bone matrix 
during remodeling. 
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Figure 1.2. Structure of R-spondin. (A) R-spondins contain an N-terminus that contains a 
putative secretion signal, two furin repeats in a furin domain, a TSR1 domain, and a C-terminus. 
(B) The TSR1 domain of R-spondin conserves both the tryptophan rich region (single line) and 
the cysteine-rich CSVTCG region (double line). The valine in the prototypical TSR1 is replaced in 
the R-spondins with four amino acids that are basic and polar. 
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Figure 1.3. Signaling by R-spondin. This diagram demonstrates the role of R-spondin in 
regulating canonical Wnt signaling. During the process of canonical Wnt signaling, Wnt binds to 
Frizzled and LRP5/6. This binding promotes interaction with Axin. When Axin is bound to the 
receptor complex, this prevents Axin interaction with GSK3beta and APC. GSK3beta is then 
unable to phosphorylate beta-catenin which results in beta catenin stabilization and nuclear 
localization to interact with TCF/LEF transcription factors. When GSK3beta is active it results in 
beta-catenin phosphorylation and increased beta-catenin degradation following ubiquitination 
and proteasomal degradation. R-spondins regulate this canonical signaling process by inhibiting 
the action of ZNRF3. ZNRF3 acts as a Wnt signaling inhibitor by promoting LRP/Fzd turnover. 
When Rspo is bound to a LGR receptor it blocks the turnover inhibiting activity of ZNRF3. 
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CHAPTER 2: R-Spondin-2 is an osteoblast-produced Wnt agonist that regulates 
osteoblastogenesis 
 
2.1 INTRODUCTION 
Bone remodeling is critical for the maintenance of bone mass and structure, and is 
particularly important when considering pathologies that disrupt homeostasis, such as those 
that lead to the development of low-bone mass and osteoporosis. This decrement in bone mass 
and structure and the concordant decrease in mechanical strength can be caused both by 
dysregulation of osteoblastic and osteoclastic activity (Langdahl et al., 2016). Therapeutics to 
restore bone mass and strength therefore focus on targeting one of these two processes.  
A potent positive regulator of bone deposition by osteoblasts during bone modeling and 
remodeling is the canonical Wnt signaling pathway, making it a highly desirable target for 
therapeutics to increase bone formation. The Wnt pathway has been deeply investigated in the 
context of bone, focusing on both extracellular pathway modulators and the stabilization of 
beta-catenin and transcription factors, generally with increases in canonical signaling through 
the pathway leading to increased osteoblastogenesis and bone formation (Monroe et al., 2012). 
Modulation of the pathway through antibodies targeting Sclerostin, an antagonist of canonical 
Wnt signaling in bone, has been particularly successful (Lim and Bolster, 2017). These 
antibodies, along with PTH and PTHrP analogs teriparatide and abaloparatide, are currently the 
only osteoanabolic therapeutics; other interventions primarily focus on inhibiting the further 
resorption of bone by osteoclasts, such as the bisphosphonates (Fukumoto and Matsumoto, 
2017).  There remains a critical need for the identification of additional osteoanabolic 
therapeutic options given the limitations, in terms of clinical use of the currently available 
therapeutics.  
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The R-spondin proteins, a family of four secreted matricellular proteins, potentiate Wnt 
signaling and may represent a novel focus of therapeutic targeting to modulate osteoblasts. The 
R-spondins activate canonical Wnt signaling by binding to the Leucine-Rich Repeat-Containing G-
Protein Coupled Receptors 4-6 (LGR4-6), which then interacts with the E3-Ubiquitin ligases 
ZNRF3/RNF43 to inhibit Wnt receptor turnover (Hao et al., 2012; Koo et al., 2012). R-spondins 
are also reported to activate non-canonical Wnt/Planar Cell Polarity (PCP) signaling (Ohkawara 
et al., 2011). All four R-spondin family members have a similar modular domain structure: an N-
terminal signal sequence, two furin-like/cysteine-rich domains, a thrombospondin type-1 motif 
(TSR1), and a basic amino acid rich C-terminus, which are encoded on separate exons 
(Hankenson et al., 2010). Each of the R-spondins are expressed in the developing mouse limb, as 
well as in other tissues, and each has different functional effects with respect to the skeleton. R-
spondin-1 (Rspo1) disruption is not associated with a skeletal phenotype, but its expression is 
induced during osteoblastogenesis and in response to vibration (Wang et al., 2013). The Rspo2 
knockout mouse (Rspo2ftl) is perinatal lethal due to defective lung development and exhibits 
limb and craniofacial malformations (Bell et al., 2003; Bell et al., 2008). Our laboratory has 
previously demonstrated that Rspo2 is highly expressed in Wnt11-overexpressing pre-
osteoblasts. Furthermore, both overexpression and recombinant addition of Rspo2 enhanced 
osteoblastogenesis in vitro (Friedman et al., 2009). Rspo3 disruption is embryonic lethal due to 
angiogenic defects in the murine placenta, though conditional knockout in limb mesenchyme 
(via Prx1-Cre recombinase-mediated disruption) exacerbated Rspo2 limb malformations in 
double knockouts (Aoki et al., 2007; Neufeld et al., 2012; Knight and Hankenson, 2014). Rspo4 
mutations in humans lead to anonychia, but a skeletal phenotype has not been identified 
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(Bergmann et al., 2006; Nam et al., 2007b). It is clear that R-Spondins influence several aspects 
of skeletal biology, but their cell-specific roles in vivo have yet to be elucidated. 
The clear anabolic in vitro effects of Rspo2 on osteoblastogenesis led us to investigate 
the mechanisms through which Rspo2 affects osteoblastogenesis. We utilized limb bud 
progenitor cells from the global knockout Rspo2ftl mouse model to evaluate Rspo2-deficient 
osteoblastogenesis in vitro. Further, due to the perinatal lethality of this model, we generated a 
conditional floxed Rspo2 allele. We crossed this model to a pan-expressing Cre mouse (EIIa-cre) 
and recapitulated the complete knockout phenotype. Next we crossed the floxed mouse to a 
mouse line that expresses Cre-recombinase under the control of the Osteocalcin (Ocn) promoter 
for specific recombination in osteoblasts to determine the function of Rspo2 in osteoblasts in 
postnatal bone. At 1 month, 3 months, and 6 months of age, we evaluated the skeletal 
phenotype of these mice by μCT, histomorphometry, mechanical testing, and analysis of 
progenitor cell populations. Herein, for the first time, we show that Rspo2 is an osteoblast 
autocrine factor that impacts bone development and adult bone mass accrual.  
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2.2 METHODS 
Animals: 
Animals were housed in a pathogen-free vivarium in accordance with institutional policies.  
Rspo2ftl mice were used for limb bud mesenchymal progenitor cell isolation. Ella-Cre mice were 
obtained from Jackson Laboratories. Ocn-Cre mice were obtained from Dr. Tom Clemens, Johns 
Hopkins University (Zhang et al., 2002). Mice were humanely euthanized at 1, 3, and 6 months 
of age for skeletal phenotyping. 
 
Generation of Rspo2flox mice: 
To create the Rspo2 conditional, or floxed, allele (Rspo2floxed), we generated a targeting 
construct in which a 2.9 kb genomic DNA fragment containing exons 4 and 5 was flanked by loxP 
sites (Fig. 1a). The 5′ homology arm was 2.9 kb in length and the 3′ homology arm was 4.7 kb in 
length. We used the targeting construct, which also contained a neomycin resistance cassette 
flanked by Frt sites, to electroporate V6.5 ES cells, which are derived from C57BL/6 x 129/Sv 
hybrid embryos. ES cell clones were identified as targeted by Southern blot analysis using 
probes flanking the 5′ and 3′ ends of the targeting construct. ES cell lines were then karyotyped, 
and one targeted line with no karyotype abnormalities was injected into C57BL/6 embryos to 
generate chimeric mice. Subsequently, we crossed Rspo2flox mice with C57BL/6 mice for 4 to 6 
generations before crossing them with mice expressing the Cre recombinase. 
Cell type-specific deletion of Rspo2fl allele: 
The Cre-transgenic mice used in this study have been previously described: EIIa-Cre (Lakso et al., 
1996) and Ocn-Cre (Zhang et al., 2002). We crossed hemizygous Cre transgenic mice with 
homozygous Rspo2flox mice to generate heterozygous Rspo2flox offspring with and without a Cre 
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allele. We then crossed homozygous Rspo2flox mice with heterozygous Rspo2flox mice to generate 
the following offspring: WT mice, mice hemizygous for a Cre allele, mice homozygous for the 
Rspo2flox allele, hereafter referred to as Rspo2f/f, and Rspo2f/f mice that were also hemizygous for 
a Cre allele. We genotyped offspring by PCR using the following primer sequences: Cre-for, 5′- 
TTACATTGGTCCAGCCACC-3′, Cre-rev, 5′-ACCAGCCAGCTATCAACTCG-3′, product size 102 bp; 
Rspo2-floxB-for, 5′-GCACTGTCCAGGAGGTAGGTCTAAAC-3′, Rspo2-floxB-rev, 5′- 
CCTTCTTCTGAGCACCATCTGC-3′, product size 359 bp (WT) and 413 bp (floxed allele). Rspo2-
floxB-for and Rspo2-floxB-rev were combined with Rspo2-floxA-for 5’-
GACTCTTACTGCCTGGGATCCTCATT-3’ to assess recombination with a product size of 512bp. 
 
Skeletal Preparations: 
Rspo2f/f males were time-mated with Rspo2f/+;Ella-Cre+ females. e16.5 and e18.5 mouse 
embryos were harvested, digested, and stained with Alizarin Red S and Alcian Blue by standard 
methods (Rigueur and Lyons, 2014). 
 
Micro-Computed Tomography: 
Femurs were dissected, cleaned of soft tissue, and wrapped in PBS-soaked gauze. The wrapped 
femurs were loaded into 9.0 mm diameter scanning tubes and imaged in a micro-computed 
tomography (µCT) scanner (model μCT50, Scanco Medical, Wayne, PA, USA). Femurs were 
scanned using the following parameters: 6.0 μm isotropic voxel size, 55kVp, 145 μA, 1000 
projections per 180°, and 1500 ms integration time. Cortical bone parameters were measured 
by analyzing 50 slices in the mid-diaphysis. This defined region was the central portion between 
the proximal and distal ends of the femur. A semi-automated contouring method was used to 
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determine the outer cortical bone perimeter. Briefly, a user-defined contour was drawn around 
the cortical bone perimeter of the first slice. This initial estimate was then subjected to 
automated edge detection. This contour then served as the initial estimate for the next slice, 
with the contouring process continued for all 100 slices. A fixed, global threshold (300mg 
HA/cm3) of the maximum gray value was used to distinguish bone from soft tissue and marrow. 
Trabecular bone parameters were measured by analyzing 150 slices of the distal metaphysis. 
Briefly, the distal end of the analysis region was chosen to be just proximal to the end of the 
primary spongiosa in the marrow cavity. This assured that only trabecular bone was analyzed. 
Starting at this image, a user-defined contour was drawn to include trabecular bone within the 
marrow cavity and exclude cortical bone. User-defined contours were drawn every 15-30 slices 
and an automated morphing program was used to interpolate the contours for all images in 
between. A fixed, global threshold of 220 mg HA/cm3 was used to distinguish trabecular bone 
from soft tissue and marrow. A Gaussian low-pass filter (σ = 0.8, support = 1) was used for all 
analyses. Nomenclature is reported as previously described(Bouxsein et al., 2010). 
 
Histology:  
Tibias were dissected and fixed in fresh 4% paraformaldehyde at 4º C for 24 hours and then 
decalcified in 12% EDTA for 1 week. After decalcification, tibias were embedded in paraffin and 
7um longitudinal sections were obtained. Hematoxylin and Eosin (H&E) and Alcian Blue 
Hematoxylin/Orange G (ABH/OG) staining was done by standard methods. For staining of 
tartrate-resistant acid phosphatase (TRAP), after de-paraffinization and rehydration, sections 
were incubated with acetate buffer containing naphthol-AS-BI-phosphate and Fast Red Violet at 
37ºC for 30 minutes. The sections were then counterstained with 0.1% Fast Green.  
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Histomorphometry: 
For dynamic histomorphometric analysis of bone formation, all animals were labeled with 
alizarin complexone and calcein. At 4, 6, or 8 days before euthanasia (for 1-, 3-, and 6-month-old 
mice, respectively), alizarin complexone was administered subcutaneously at a dose of 30mg/kg. 
At 1 day before euthanasia, calcein was administered subcutaneously at a dose of 20mg/kg. At 
harvest, right tibias were stripped of soft tissues, bisected, and immediately fixed in 70% ethanol 
under vacuum. Tibias were embedded in methyl methacrylate without decalcification. Sagittal 
sections of the proximal portion of the tibias were cut at 6μm thickness, and sections were 
stained with Goldner’s Trichrome. Histomorphometrical analysis was performed using 
BioQuant® OSTEO Software. All parameters were calculated according to the recommendations 
of the Histomorphometry Nomenclature Committee of the American Society of Bone and 
Mineral Research (Dempster et al., 2013).  
 
Biomechanical Testing: 
Right femora were subjected to 3-point bending by standard techniques after microCT analysis 
at the Penn Center for Musculoskeletal Disorders Biomechanics Core.  Femora were loaded in 
the anterior-posterior direction at 0.03 mm/s using a electromechanical testing machine 
(Instron 5542, Instron Inc., Norwood, MA) with the posterior side in tension between lower 
supports that were 7.66mm apart for the 1-month samples and 11.79mm apart for the 3-month 
and 6-month samples, with the upper loading pin in the center of the lower supports. All bones 
were tested at room temperature and kept moist with PBS. Crosshead displacement was 
obtained via the Instron system and load data were collected with a 10N load cell (Instron Inc., 
Norwood, MA) at a sampling frequency of 100 Hz. Load-displacement curves were analyzed for 
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whole bone stiffness and ultimate load using custom computational code (MATLAB R2015a; 
Mathworks Inc., Natick, MA, USA). 
 
Bone Marrow-Derived Cell Culture: 
Bone marrow cells were harvested from the left femur of 1-, 3-, and 6-month old mice. Whole 
marrow was expelled from the bone with several flushes through a 25-gauge needle. Single-cell 
suspensions were made by aspiration and expulsion of the marrow through an 18-gauge needle. 
Cells were strained through a 70µm cell strainer and then counted. Cells were pelleted and 
resuspended in MSC media (αMEM supplemented with 10% FBS, L-glutamine, 100IU/mL 
penicillin, 100mg/mL streptomycin). 4x106 cells were plated on 60mm dishes in duplicate for 
CFU-F analysis. Colonies were allowed to grow for 12 days and then stained for Alkaline 
Phosphatase with Fast Red as a counterstain. Colonies were counted using a dissecting 
microscope. The remaining cells were plated on 100mm dishes for expansion. At the first 
passage, cells were seeded at 2.5 x 104 cells/cm2 into 48-well tissue culture plates and grown to 
confluence in MSC media, at which point they were cultured in osteopermissive media (OPM: 
αMEM supplemented with 10% fetal calf serum, 100x L-glutamine, 100 IU/mL penicillin, 100 
mg/mL streptomycin, 32.3 µg/mL ascorbic acid 2-phosphate, 5 mM β-glycerophosphate). Cells 
were then fixed in formalin for 10 minutes and incubated in 2% Alizarin red S (pH 4.25) for 20 
minutes. Excess Alizarin red S was removed and then calcium-bound Alizarin was extracted by 
treating with 10% (w/v) acetic acid, heating, and adjusting the pH to 4.1-4.5 with 10% 
ammonium hydroxide. Total mineral content was then measured colorimetrically at 405 nm 
using a spectrophotometer.  
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Limb Bud Mesenchymal Progenitor Cell (MPC) Culture: 
Heterozygous Rspo2ftl mice were time-mated and embryos were harvested at e16.5. Limbs were 
dissected from the embryos, stripped of their autopods and soft tissues, and minced. They were 
then placed in media and aspirated and ejected through an 18-gauge needle 10 times. The 
media and tissue mixture was then plated on a 10cm plate and the adherent population was 
selected. The resultant cells are able to undergo osteogenesis as seen by ALP staining and 
Alizarin red S staining of mineral, as well as adipogenesis as seen by Oil Red O staining of lipid 
(data not shown). For osteogenesis, cells were seeded at 2.5 x 104 cells/cm2 in 6- or 48-well 
tissue culture plates. The next day, cells were transferred to osteogenic media (OGM: αMEM 
supplemented with 10% fetal calf serum, 100x L-glutamine, 100 IU/mL penicillin, 100 mg/mL 
streptomycin, 32.3 µg/mL ascorbic acid 2-phosphate, 5 mM β-glycerophosphate, 2.5nM rhBMP-
6 [R&D Systems]). 10nM Recombinant RSPO2 [R&D systems] was added during rescue 
experiments. Protein isolation was performed at 24 hours for western blotting. RNA isolation 
occurred at 24 hours, 5 days, 10 days, and 15 days. ALP staining occurred at 5 and 7 days. 
Alizarin red S staining of mineral occurred at 10 days, 15 days, and 20 days. 
 
Western Blotting: 
Cells were lysed in RIPA buffer in the presence of Phosphatase and Protease Inhibitor cocktails 
(Pierce and Roche, respectively). Lysates were separated on 4-20% gradient SDS-PAGE gels and 
transferred to nitrocellulose membranes. After blocking with Odyssey Blocking Buffer (Licor) for 
30 min, blots were incubated with the following primary antibodies: Anti-RSPO2 (sc-292494, sc-
74883), Anti-Active Beta-Catenin (Millipore 05-665), Anti-Total Beta-Catenin (BD Transduction 
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610154), and Anti-Beta-Tubulin (Sigma T7816). This was followed by incubation with the 
appropriate secondary antibody (Li-Cor) and imaging on a Li-Cor Odyssey CLx.  
 
Gene Expression: 
Cells were collected in TRIzol Reagent for RNA isolation. The Directzol RNA isolation kit (Zymo) 
was used for RNA purification according to the manufacturer’s instructions. 1µg RNA was 
reverse-transcribed to cDNA using the Applied Biosystems High-Capacity cDNA Reverse 
Transcription kit. Gene expression was quantified using a ViiA 7 Real-Time PCR System (Applied 
Biosystems) with a 10µL reaction volume containing: 0.5µL cDNA, 0.5µM forward and reverse 
primers, and 1x PowerUp SYBR Green Master Mix (Applied Biosystems). For each gene of 
interest, samples were analyzed in triplicate and control wells were simultaneously analyzed to 
rule out DNA contamination and primer dimer binding. Proper amplicon production was 
confirmed by melt curve analysis. Data were normalized to the housekeeping gene 18S rRNA 
and presented as fold-change expression relative to WT whole bone, calculated using the 
formula 2− ΔΔC(t). 18S C(t) values were stable across treatment groups.  Primer sequences are 
available upon request.  
 
Statistics: 
Two-way ANOVA or Student’s t-test was used to detect statistically significant treatment effects, 
after determining that the data were normally distributed and exhibited equivalent variances. 
All t-tests were two-sided and unpaired. Tukey corrections were used for multiple comparisons 
during the two-way ANOVA. P-values less than 0.05 were considered statistically significant.   
While statistically significant differences do exist between male and female mice of both control 
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and Rspo2f/f mice, they are consistent with well-established sex differences in bone geometry in 
mice and are not reported herein.   
 
2.3 RESULTS 
Rspo2-null Limb-bud Mesenchymal Progenitor Cells have defective osteoblastogenesis 
Our previous work demonstrated that Rspo2 was required for Wnt11-mediated 
osteoblastogenesis in MC3T3E1 cells, but the autocrine role of Rspo2 in primary osteoblasts was 
not examined (Friedman et al., 2009). MSC were harvested from Rspo2Ftl mouse limb bud 
mesenchyme.  These cells undergo osteoblast differentiation in the presence of BMP but not 
with ascorbic acid and inorganic phosphate alone.  MSC isolated from Rspo2Ftl mice (deficient in 
Rspo2) showed reduced osteoblastogenesis (Figure 2.1).  Mineralization was significantly 
reduced in Rspo2Ftl MSC compared to MSC from wildtype littermates (Figures 2.1A,B), a 
difference that could be rescued with the addition of recombinant RSPO2 to the media (Figure 
2.1C). Despite the contrast in mineralization, there was no apparent difference in alkaline 
phosphatase staining between the genotypes (Figure 2.1D).  To better understand the 
mechanism of reduced mineralization in the Rspo2 deficient cells, osteogenic gene expression 
was studied using RT-qPCR. There was no difference in the expression of Runx2, the master 
regulator of osteogenesis (Figure 2.1E). However, the downstream early marker of osteogenesis, 
Osterix (Osx), was significantly reduced in the Rspo2Ftl MSC after 5 days of osteogenesis (Figure 
2.1F) and remained decreased over the course of osteoblastogenesis (data not shown). The late-
stage osteoblastogenesis marker of osteoblasts, Osteocalcin (Ocn), had reduced expression in 
the Rspo2Ftl cells at 10 days of differentiation (Figure 2.1G), though this difference diminished 
with further differentiation (data not shown). In contrast, bone sialoprotein (BSP), another late-
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stage osteoblastogenesis marker that is involved in the mineralization of the matrix, did not 
show differences in expression in the Rspo2Ftl MSC compared to the wild-type control cells 
(Figure 2.1H).  
Generation of R-Spondin-2 Conditional Allele 
The perinatal lethality of the Rspo2 knockout mice prevents the examination of the impact of 
Rspo2 on osteoblastogenesis and bone formation in post-natal bone.  The R-spondin-2 allele 
proved difficult to target using the most common strategies for loxP site selection as the gene 
contains very large introns that are in-frame. Thus, we targeted the disruption of the Furin and 
TSR repeats of the R-spondin-2 gene (Figure 2.2A).  Previous work has shown that such 
disruption results in a complete disruption of beta-catenin-mediated function (Kim et al., 2008). 
A targeting construct with loxP sites flanking exons 4 and 5 was designed and used to target 
V6.5 ES cells. ES Cells were screened for appropriate targeting by Southern blot analysis for both 
arms of the construct, PCR identification of the downstream loxP site, and karyotype analysis. 
Injection of the successfully targeted ES cells into C57BL/6 blastocysts resulted in 13 chimeric 
pups, which were crossed to C57BL/6 mice for production of the F1 generation and 
determination of germline transmission. Of the 43 F1 mice produced, 17 were confirmed via 
PCR to be heterozygous for the targeted allele for both loxP sites. The construct was determined 
to be intact via Southern blot analysis for both arms of the targeting construct. The targeting 
construct was designed with an intronic deletion permitting the use of a single pair of PCR 
primers flanking the downstream loxP site for genotyping. The floxed allele yields a 359bp 
fragment, while the wild-type allele yields a 413bp fragment. The genotyping can also be 
combined with the forward primer from the upstream loxP site for determination of 
recombination when Cre recombinase is present, which yields a 512bp fragment (Figure 2.2B).  
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When this construct was expressed in cells with Cre-recombinase, an antibody corresponding to 
the C-terminus of RSPO2 confirmed decreased RSPO2 protein levels compared to cells not 
expressing Cre-recombinase (Figure 2.2C).  
 
Recapitulation of Rspo2ftl Phenotype with Ella-Cre Expression 
To test the functional significance of the Rspo2 allele in vivo, Rspo2floxed mice were crossed with 
the pan-Cre expressing EIIa-cre mouse line, which has whole-body Cre-recombinase expression 
when the allele is inherited from the dam. Three litters from f/f Cre-negative x f/wt Cre-positive 
matings were aged to weaning. At P21, no EIIa-Cre+Rspo2f/f mice were identified. The genetic 
frequency was consistent with perinatal lethality of the EIIa-Cre+Rspo2f/f mice similar to the 
Rspo2Ftl global knockout (Tables 1-2), with the other four possible genotypes each accounting 
for approximately one third of the total offspring. Skeletal preparations of E16.5 and E18.5 pups 
from similar matings were stained with Alcian blue and Alizarin red S. All Ella-Cre+Rspo2f/f pups 
had dysmorphic distal phalanges with decreased mineralization (10/10 embryos), and several 
pups additionally had reduced (8/10 embryos) or absent digits (4/10 embryos) (Figures 2.2D-I), 
consistent with the phenotype of the three models of Rspo2 global knockouts that have been 
previously published (Bell et al., 2003; Nam et al., 2007a; Aoki et al., 2008; Bell et al., 2008; 
Yamada et al., 2009).  As may be expected with a Cre mediated knockout, there was 
heterogeneity in the embryo phenotypes.  Figures 2.2E and 2.2H show the least severe 
phenotypes of the pelvic and thoracic limbs, respectively, with reduced distal phalangeal 
mineralization in the distal limb. Figures 2.2F and 2.2I show limbs of more severely affected 
individuals. 
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Osteoblast-specific knockout results in decreased body size, bone mass, and bone strength 
Next, the Rspo2floxed mice were crossed with Osteocalcin-Cre mice to disrupt Rspo2 selectively in 
mature osteoblasts.   Mice were measured (length and weight) at 3 weeks of age and then 
harvested at 1 month, 3-month, and 6-months of age for skeletal analysis of juvenile, young 
adult, and mature adult bone, respectively. At 3 weeks of age, targeted (homozygous Rspo2floxed, 
Ocn-Cre-positive, herein referred to as Ocn-Cre+Rspo2f/f) mice weighed less and had shorter 
crown-rump measurements than their control (homozygous Rspo2floxed, Ocn-Cre-negative, 
herein referred to as WT) littermates (Figures 2.3A-C). At all timepoints, the femurs of Ocn-
Cre+Rspo2f/f mice were significantly shorter than those of their control littermates (Figures 2.3D-
F). Microcomputed Tomography (μCT) was used to evaluate trabecular and cortical bone of the 
right femur from mice at all timepoints. The phenotype was most pronounced at 3 months of 
age. At this timepoint, bone volume (BV) and bone volume fraction (BV/TV) were significantly 
decreased in the Ocn-Cre+Rspo2f/f mice, with trabecular thickness being the main contributor to 
this difference (Figures 2.4A-C). The difference in trabecular bone was more pronounced in male 
mice, with female targeted mice only trending to have decreased trabecular bone. Trabecular 
and cortical tissue mineral densities were not different between groups (Figures 2.4D,E). In 
cortical bone, 3-month-old mice had decreased cortical bone volume, decreased cortical 
thickness, decreased endosteal and periosteal perimeters, and decreased polar moment of 
inertia (Figures 2.4F-I). However, when males and females are considered separately, only 
targeted male mice showed significant reductions in these parameters. At 1 month of age, Ocn-
Cre+Rspo2f/f mice had decreased BV and BV/TV compared to their control littermates (Figure 
2.5A-B). The decreased BV/TV ratios corresponded to both decreased trabecular number and 
decreased trabecular thickness (Figures 2.5C-D). The tissue mineral density of the trabecular 
35 
 
bone and cortical bone did not differ across genotypes (Figure 2.5D-E). At 1 month of age, no 
significant differences were identified in the cortical bone parameters (Figures 2.5F-H). At 6 
months of age, Ocn-Cre+Rspo2f/f mice demonstrated decreased BV and BV/TV, which was again 
primarily due to decreased trabecular thickness rather than trabecular number (Figures 2.6A-C). 
The tissue mineral densities of trabecular and cortical bone were not different between groups 
(Figures 2.6D-E). While cortical BV and cortical thickness still showed a decreasing trend in the 
Ocn-Cre+Rspo2f/f mice at 6 months, these parameters were no longer statistically significant 
(Figures 2.6F). Endosteal and periosteal perimeters and polar moment of inertia were not 
different between groups (Figure 2.6G-H, data not shown). Three dimensional reconstructions 
of trabecular and cortical bone of mice from the middle BV/TV and cortical thickness, 
respectively, are shown (Figures 2.4I-J, 2.5I-J, 2.6I-J). Right femora were subjected to 
biomechanical testing via 3-point bending. At 3 months of age, Ocn-Cre+Rspo2f/f mice had 
decreased maximum load force, corresponding to a weaker bone. They also had significantly 
decreased bending stiffness (Figures 2.4K-L). There were no differences in the maximum load 
force or bending stiffness at 1 month of age, however at 6 months of age, the male mice had 
decreases in both parameters (Figures 2.5K-L, 2.6K-L). 
 
Osteoblast-specific Rspo2 knockout mice have decreased bone mass and mineral apposition rate 
 Static and dynamic histomorphometric analysis of trabecular bone of proximal tibiae from 1-
month-old mice was performed to further assess bone microarchitecture as well as to assess 
bone formation. Representative histologic sections from WT (Figures 2.7A,C) and Ocn-
Cre+Rspo2f/f (Figures 2.7B,D) littermate mice are shown. TRAP-stained sections and double-
labeled bone sections from WT (E,G) and Ocn-Cre+Rspo2f/f mice (F,H), respectively, are also 
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shown. Similar to the microCT analysis, targeted mice had decreased trabecular BV/TV primarily 
due to a corresponding decrease in trabecular thickness, though there is a small but significant 
reduction in the trabecular number as well (Figures 2.7I-K). Consistent with this, the bone 
surface to bone volume ratio was increased in Ocn-Cre+Rspo2f/f mice (Figure 2.7L). However, 
while the total number of osteoblasts was reduced in the targeted animals, the number of 
osteoblasts per bone surface was not different between groups (Figure 2.7M). Additionally, we 
measured the interlabel distance between the two fluorescent bone labels to calculate the 
mineral apposition rate. The mineral apposition rate was significantly decreased in the Ocn-
Cre+Rspo2f/f mice compared to their control littermates (Figure 2.7N). The mineralizing surface 
(MS/BS) was calculated by measuring the fluorescently single- and double-labeled surfaces, and 
this was also not different between the groups (Figure 2.7O). The bone formation rate (BFR/BS) 
was calculated to assess the combined contributions of mineralizing surface and mineral 
apposition rate. The BFR was reduced in the Ocn-Cre+Rspo2f/f mice (Figure 2.7P). 
 
Decreased progenitor cell population and mineralization of BM-MSC from the conditional 
knockout model 
Finally, bone marrow-derived MSC (BM-MSC) were isolated from WT and Ocn-Cre+Rspo2f/f mice 
for analysis of osteoblastogenesis and progenitor population. BM-MSC from targeted mice 
showed decreased mineralization as measured by Alizarin Red S staining (Figures 2.8A-B). 
However, similar to cells isolated from Rspo2Ftl mice, there was no difference in ALP staining 
(data not shown). The total mesenchymal progenitor pool and the pre-osteoblasts were 
evaluated using colony forming unit-fibroblast (CFU-F) and CFU-AP, respectively. Ocn-
Cre+Rspo2f/f mice at 1-month of age showed approximately a 50% decrease in both CFU-F and 
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the percent of cells that were CFU-ALP-positive (Figures 2.8C-D).  Similarly, at 3-months of age 
Ocn-Cre+Rspo2f/f mice showed a 33% decrease in progenitor cell colonies, and a 20% decrease 
in the percentage of ALP-positive progenitor colonies (Figures 2.8E-F). 
 
2.4 DISCUSSION 
The Wnt signaling pathway is important in bone development, osteoblastogenesis, and 
bone maintenance and remodeling, making it a popular target for research on bone anabolic 
agents. However, differential modulation of the pathway by specific ligands and cofactors, such 
as R-spondins, is not well characterized. Here, we have investigated the role of the Wnt agonist 
Rspo2 in osteoblastogenesis and in postnatal bone to elucidate its contribution to these 
processes. We utilized Rspo2-null limb bud progenitor cells isolated from Rspo2ftl mice for in 
vitro investigation. We also developed a novel Rspo2 conditional knockout mouse model for 
specific deletion of Rspo2 in mature osteoblasts.  
Rspo2-null limb bud progenitor cells have decreased osteoblastogenesis and 
mineralization, with corresponding alterations in osteogenic gene expression profile that was 
somewhat surprising. Osx-null mice do not form any bone, yet even the very low Osx expression 
seen here is sufficient for in vitro differentiation (Nakashima et al., 2002). Furthermore, 
downstream osteogenic genes such as BSP have expression levels similar to WT cells. Moreover, 
while Ocn is decreased initially, its expression reaches levels similar levels to WT cells at later 
time points in osteoblastogenesis. The combination of these data suggests that there is a 
mechanism for bone formation without significant Osx expression, and that there is 
transcriptional regulation that allows downstream genes to be expressed at normal levels. 
Consistent with this, Lrp5 knockout calvarial osteoblasts had no change in the expression of 
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Runx2, but did have a significant decrease in the expression of Osx (Riddle et al., 2013). They 
also had decreased mineralization with no change in ALP staining, as we observed in the both 
the Rspo2-null limb bud progenitor cells and BM-MSC. Comparatively, Lrp6 knockout calvarial 
osteoblasts had reductions in both mineralization and ALP staining, as well as moderate 
decreases in the expression of Runx2, Osx, and Ocn, suggesting an even earlier and more 
sustained role for Lrp6 in osteoblastogenesis (Riddle et al., 2013). Clearly, the osteoblast-specific 
Rspo2 knockout shares many of these characteristics, which could possibly be due to 
modulation of both Lrp5 and Lrp6 levels at the membrane.  In this work we have not attempted 
to evaluate how Rspo2 may modulate Lrp5 and/or Lrp6 specifically.   
In vivo, osteoblast-specific Rspo2 knockout resulted in a decrease in overall body mass 
and femur length. Via microCT analysis, we identified significant reductions in the trabecular 
bone volume fraction, trabecular thickness, and trabecular number, with modest reductions in 
cortical bone mass at the 3 month timepoint. The reduced bone mass is most pronounced at the 
earlier timepoints (1 and 3 months of age), corresponding to the periods of highest growth and 
peak trabecular bone mass in mice. By 6 months, the differences in trabecular bone have 
lessened, and the cortical bone is no longer significantly different from WT littermates. Bending 
analysis reflected the significant differences seen in the cortical bone on microCT at 1 and 3 
months of age. At 6 months of age, male mice had significant reductions in the maximum load 
force and bending stiffness, while the microCT data only showed a trend toward reduction.  
Our histomorphometry data show that Rspo2 deficiency in osteoblasts results in 
decreased mineral apposition in despite of similar numbers of osteoblasts per bone surface, 
suggesting a deficiency in osteoblast activity. Further supporting this, while the mineralizing 
surface fraction is similar to wild-type animals, the decreased bone formation rate confirms a 
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decreased overall production of new bone. This corresponds to our in vitro mineralization data 
for both the Rspo2-null limb bud progenitor cells (Figure 2.1) as well as BM-MSC from the 
targeted Rspo2floxed mice (Figure 2.8). Interestingly, the progenitor cell population in the bone 
marrow of our Ocn-Cre+Rspo2f/f mice showed decreases in both total colony number and 
percentage of ALP-positive colonies by CFU-F analysis. Despite this decreased 
osteoblastogenesis potential, the mice have similar numbers of osteoblasts per bone surface 
compared to WT littermates, suggesting that this diminished osteoblastogenesis is still sufficient 
to produce osteoblasts during growth. Whether this progenitor pool and differentiation 
potential are still adequate during aging or in the face increased demands such as ovariectomy 
or fracture remains to be investigated. Overall, Rspo2 deficiency causes a decrease in 
osteoblastogenesis and mineralization both in vitro and in vivo, and this deficiency leads to 
decreased bone mass in mice. 
The decreased bone length seen here presents an intriguing question, given that the 
length of the long bones is primarily determined by appropriate function of the growth plate. 
The Osteocalcin promoter used to express Cre in this model is also expressed in late 
hypertrophic chondrocytes, which may provide a mechanism for abnormality in the growth 
plate (Zhang et al., 2002). Deficiency of Rspo2 in chondrocytes has been reported to decrease 
chondrocyte proliferation, but differences in protein expression in the hypertrophic zone were 
not noted (Takegami et al., 2016). However, canonical Wnt signaling is known to affect 
progression of chondrocytes through the growth plate, and, consistent with this, Lrp5 knockout 
mice also have shortened femoral length (Kato et al., 2002). Given that hypertrophic 
chondrocytes are known to transdifferentiate to osteoblasts, it is possible that the Rspo2 
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deficiency hinders the activation of the pluripotent stem cell programs required for this process 
(Bahney et al., 2014; Zhou et al., 2014). 
The overall skeletal phenotype of the osteoblast-specific knockout of Rspo2 is consistent 
with that seen in other disruptions of canonical Wnt signaling in bone, specifically that of Lrp5 
disruption, albeit somewhat attenuated (Gong et al., 2001; Holmen et al., 2004). Specifically, the 
Lrp5 knockout mouse has decreased bone mass, decreased mineral apposition rate, decreased 
osteoblast numbers, and decreased femoral length, all of which are similar to the phenotype 
seen with osteoblast-specific knockout of Rspo2 (Kato et al., 2002). Despite these post-natal 
effects, overall skeletal development, similar to the osteoblast-specific Rspo2 knockout reported 
here but in contrast to the global Rspo2 knockout, is relatively normal. When the Lrp5 knockout 
mouse is crossed with the Lrp6 knockout mouse to create double knockouts, skeletogenesis 
defects emerge similar to those seen in the Cttnb1 (Beta-catenin) and Rspo2 global knockout, 
although with different left/right and anterior/posterior patterns (Holmen et al., 2004; Hill et al., 
2005). LRP5 and LRP6 are the transmembrane co-receptors mediating canonical Wnt signaling, 
along with the Frizzled receptors, and are regulated by ZNRF3 and RNF43, which are themselves 
inhibited by Rspo2 (Hao et al., 2012; Koo et al., 2012). Therefore, the consistency of the Ocn-Cre 
Rspo2-deficient phenotype with Lrp5 deficiency corroborates the hypothesis that Rspo2 
modulates canonical Wnt signaling in bone likely through modulation of Lrp5 and perhaps Lrp6 
receptors.  While not examined, it is probable that the absence of Rspo2 produced by 
osteoblasts, results in decreased Lrp5/6 receptors on osteoblasts.  Additional studies utilizing 
combined knockouts of Rspo2 with these receptors would help elucidate this interaction. 
The microCT results show consistently decreased trabecular bone in the 1-, 3-, and 6-
month old mice, primarily due to decreased trabecular thickness. However, the phenotype does 
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not increase in severity from 3 to 6 months. This is likely due to the fact that this is primarily a 
period of bone resorption therefore the defective mineralization seen in our model may be less 
significant during this time period (Jilka, 2013). While there are corresponding decreases in 
osteoclasts seen via TRAP staining, these are only sufficient to moderately attenuate the 
difference between the groups. This phenotype contrasts with the Wnt10b-null mouse model in 
which the growth rate and bone mass are normal to enhanced at 1 month of age, but 
progressive osteopenia develops thereafter (Stevens et al., 2010). The differences in cortical 
bone parameters also lessen to the point of no longer being different at 6 months of age. This 
may possibly be due to smaller magnitude differences and a lack of statistical power in this 
study; however, Wnt signaling phenotypes in bone have shown unique phenotypes depending 
on the signaling molecules targeted.  As an example, over expression of Wnt10b increases 
trabecular bone, with minimal impact on cortical bone (Bennett et al., 2007). Additionally, 
biomechanical testing demonstrated decreased bone strength via 3-point-bending at 3- and 6- 
months of age, which corresponds primarily to cortical bone strength due to force application at 
the mid-diaphysis. Though there were no significant differences in cortical bone parameters via 
microCT at 6 months, the mechanical testing was able to detect differences in the bone with 
greater sensitivity. Further studies to age our novel model to a geriatric timepoint are needed to 
determine whether Rspo2-deficient mice are able to maintain their bone mass or if the 
phenotype becomes more severe over a longer time period. As well, investigation into the 
coupling of osteoblasts and osteoclasts in the face of Rspo2-deficiency may help to explain the 
lack of further loss of bone mass from 3 to 6 months seen here.   
The decreased progenitor cell and pre-osteoblast populations as determined by CFU-F 
and CFU-AP respectively, are also somewhat unexpected given the similar numbers of 
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osteoblasts observed via histology. Disruptions of canonical Wnt signaling have been shown to 
decrease these parameters, such as in the Lrp5-knockout and the Wnt10b-knockout models 
(Kato et al., 2002; Stevens et al., 2010). However, high levels of expression of stabilized beta-
catenin decreased the number of CFU-F colonies, while lower levels of expression enhanced the 
proliferation of MSC thereby increasing these numbers (Kim et al., 2015). In another study, 
addition of Wnt3a, a stereotypically canonical Wnt ligand, increased both total number and 
percentage of ALP-positive colonies, while addition of Wnt5a, a stereotypically noncanonical 
Wnt ligand, had no effect in this assay (Baksh and Tuan, 2007). Clearly the tuning of specific Wnt 
ligands is critical to Wnt signaling’s ultimate effects on progenitor cell renewal, proliferation, 
and differentiation. In our mouse model, the clear reduction in progenitor cell population does 
not appear to affect the number of osteoblasts present on the bone surface by 
histomorphometric analysis, which further suggests that the mechanism of the decreased bone 
mass is due to reduced functionality of the osteoblasts rather than a lack of progenitor cells or a 
decreased potential to differentiate. However, given the reduced progenitor cell population, it is 
conceivable that mice with osteoblast deficiency in Rspo2, would have a reduced regenerative 
capacity when challenged with a fracture or segmental defect, and may lose bone more quickly 
when challenged by aging or ovariectomy. 
Together, our data indicate that Rspo2 modulates osteoblastogenesis and 
mineralization, both in vitro and in vivo. Rspo2-deficiency leads to decreased mineral apposition 
and bone formation rates, and thus to fewer and smaller trabeculae and decreased overall bone 
mass. Additionally, Rspo2-deficiency results in decreased bone strength resulting from changes 
in cortical bone. This specific phenotype is similar to other models that perturb the canonical 
Wnt signaling pathway, particularly those that disrupt receptors Lrp5 and Lrp6, supporting the 
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canonical Wnt signaling pathway as the primary mechanism of Rspo2activity in osteoblasts. 
However, the clear differences between our model and previous models that disrupt specific 
Wnt ligands suggest that Rspo2 modulates the receptors that integrate the signal from many 
Wnt ligands rather than tuning one specific Wnt ligand-mediated signal. Given that the 
reduction in bone mass is more modest compared to some of the other models that disrupt Wnt 
signaling, this could be beneficial as an option to more carefully tune the activity of osteoblasts 
therapeutically. In summary, we have established Rspo2 as an important modulator of bone 
mass via its regulation of osteoblast function in postnatal bone. 
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Figure 2.1. R-spondin-2 Null mesenchymal progenitor cells undergo decreased 
osteoblastogenesis. A. Alizarin red S staining of representative wells from in vitro osteogenesis 
assay after 10 days. MM = Maintenance media, OPM = osteopermissive media with β-
glycerophosphate and ascorbic acid-2-phosphate, OGM = osteogenic media with OPM and 
2.5nM rhBMP-6. B. Overall quantification of Alizarin Red S staining of osteogenesis at 10 days, as 
shown in panel A. C. Quantification of osteogenesis at 15 days with addition of recombinant 
hRSPO2 (10nM). D. Alkaline Phosphatase (ALP) staining of similar osteogenesis assay at 5 days. 
E. Relative Runx2 expression after 5 days of osteogenesis in vitro. F. Relative Osterix expression 
after 5 days of osteogenesis in vitro. G. Relative Osteocalcin expression after 10 days of 
osteogenesis in vitro. H. Relative Bone Sialoprotein (BSP) expression after 5 days of osteogenesis 
in vitro. (n= 3 cell lines from individual animals, assay performed in triplicate), * indicates 
p<0.05.  
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Figure 2.2. Generation of R-spondin-2 Conditional Allele. A. Map of the genomic region of 
exons 3 to 6 of Rspo2 in alignment with the targeting vector with exons 4 and 5 flanked by loxP 
sites (triangles), as well as the addition of a neomycin cassette flanked by FRT sites. The targeted 
allele after homologous recombination follows, which is then in alignment with the final 
recombined allele after Cre recombination of the loxP sites. Genotyping primers are shown as 
open arrows (Primer set A dark-grey; Primer set B, light-grey), and Southern blot probes are 
denoted. B. Genotyping of mice with primers Rspo2-FloxB-for, Rspo2-FloxB-rev, and Rspo2-
FloxA-For. C. Western blot of BM-MSC harvested from mice of denoted genotypes.   Pelvic limbs 
(D-F) and thoracic limbs (G-I) from embryonic skeletal preparations. Limbs from representative 
WT embryos shown in D, G. E, G from most minorly affected EIIa-Cre+Rspo2f/f embryos.  F, H 
from more severely affected embryos. D-E,G-I from E18.5 embryos, F from E16.5 embryo. 
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Figure 2.3. Osteoblast-specific Rspo2 knockout has decreased body size. A. Comparison of WT 
(top) vs. Ocn-Cre+Rspo2f/f (bottom) mice at 3 weeks. B. Normalized weights of 3-week-old mice. 
C. Normalized Crown-Rump length of 3 weeks old mice. D. Femur length of 1-month-old mice. E. 
Femur length of 3-month-old mice. F. Femur length of 6-month-old mice. *indicates p<0.05 for 
genotype groups. # indicates p<0.05 for genotypes within sex. Blue circles = males; Red squares 
= females. 
 
 
 
 
 
47 
 
 
Figure 2.4. Targeted mice have decreased trabecular and cortical bone parameters. A-H. 
Micro-Computed Tomography (uCT) of femurs from 3-month-old mice. Femurs were analyzed 
for bone volume fraction (A), trabecular number (B), trabecular thickness (C), trabecular bone 
mineral density (D), cortical bone mineral density (E), cortical thickness (F), periosteal perimeter 
(G), and endosteal perimeter (H) I-J. Three dimensional reconstructions of mid-diaphyseal 
cortical bone (I) and metaphyseal trabecular bone (J) from representative 3-month old mice. 3-
point bending of femurs from 3-month-old mice. Femurs were analyzed for (K) Maximum Load 
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and (L) Bending Stiffness. *indicates p<0.05 for genotype groups. # indicates p<0.05 between 
genotypes within sex. 
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Figure 2.5. Targeted mice have decreased trabecular and cortical bone parameters. A-H. 
Micro-Computed Tomography (uCT) of femurs from 1-month-old mice. Femurs were analyzed 
for bone volume fraction (A), trabecular number (B), trabecular thickness (C), trabecular bone 
mineral density (D), cortical bone mineral density (E), cortical thickness (F), periosteal perimeter 
(G), and endosteal perimeter (H) I-J. Three dimensional reconstructions of mid-diaphyseal 
cortical bone (I) and metaphyseal trabecular bone (J) from representative 1-month old mice. 3-
point bending of femurs from 1-month-old mice. Femurs were analyzed for (K) Maximum Load 
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and (L) Bending Stiffness. *indicates p<0.05 for genotype groups. # indicates p<0.05 between 
genotypes within sex. 
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Figure 2.6. Targeted mice have decreased trabecular and cortical bone parameters. A-H. 
Micro-Computed Tomography (uCT) of femurs from 6-month-old mice. Femurs were analyzed 
for bone volume fraction (A), trabecular number (B), trabecular thickness (C), trabecular bone 
mineral density (D), cortical bone mineral density (E), cortical thickness (F), periosteal perimeter 
(G), and endosteal perimeter (H) I-J. Three dimensional reconstructions of mid-diaphyseal 
cortical bone (I) and metaphyseal trabecular bone (J) from representative 6-month old mice. 3-
point bending of femurs from 6-month-old mice. Femurs were analyzed for (K) Maximum Load 
and (L) Bending Stiffness. *indicates p<0.05 for genotype groups. # indicates p<0.05 between 
genotypes within sex. 
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Figure 2.7. Osteoblast-Specific Knockout of Rspo2 results in decreased mineralization and 
bone mass. A-D. Histologic sections of the proximal tibia of representative 1-month-old mice 
stained with Goldner’s Trichrome. A,C. WT control mice. B,D. Ocn-Cre+Rspo2f/f mice.  E-F. TRAP 
staining of representative histologic sections of 1-month-old mice. E. WT control mouse. F. Ocn-
Cre+Rspo2f/f mouse. G,H. Double-labeled bone sections from representative 1-month-old mice. 
G. WT control mouse. H. Ocn-Cre+Rspo2f/f mouse. I-L. Histomorphometric parameters from 1-
month-old mice. Tibias were analyzed for bone volume fraction (I), trabecular thickness (J), 
trabecular number (K), bone surface (L), osteoblasts per bone surface (M), mineral apposition 
rate (N), mineralizing surface (O), bone formation rate (P). Scale bars are 200uM in A,B; 166uM 
in C,D; 100uM in E-H. *indicates p<0.05 for genotype groups. # indicates p<0.05 for different 
genotypes within sex. Blue circles = male; red squares = females.  
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Figure 2.8. Osteoblast-specific Rspo2 knockout has decreased progenitor cells and BM-MSC 
mineralization. A. Quantification of Alizarin red S staining of 10 day osteogenesis with BM-MSC 
from 1-month-old mice. MM = Maintenance Media, OPM = Osteopermissive media with β-
glycerophosphate and ascorbic acid-2-phosphate, OGM = osteogenic media with OPM and 
2.5nM rhBMP-6. B. Alizarin Red S staining of representative wells after 10 days of osteogenesis. 
C. Quantification of total number of CFU-F colonies from bone marrow flushed from 1-month-
old mice. D. Quantification of percent ALP-positive colonies from bone marrow flushed from 1 
month-old mice. E. Quantification of total number of colonies from bone marrow flushed from 
3-month-old mice. F. Quantification of percent ALP-positive colonies from bone marrow flushed 
from 3-month-old mice. *indicates p<0.05. 
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f/+; Cre- f/+; Cre+ f/f; Cre- f/f; Cre+ 
Frequency 0.25 0.17 0.17 0.42 
N 6 4 4 10 
 
Table 1. Genetic frequency of P18.5 pups resulting from EIIa-Cre-Rspo2f/f x EIIa-Cre+Rspo2f/+ 
matings. 
 
 f/+; Cre- f/+; Cre+ f/f; Cre- f/f; Cre+ 
Frequency 0.36 0.29 0.36 0 
N 5 4 5 0 
 
Table 2. Genetic frequency of P21 pups resulting from EIIa-Cre-Rspo2f/f x EIIa-Cre+Rspo2f/+ 
matings. 
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CHAPTER 3: DISCUSSION 
 
3.1 SUMMARY 
 The Wnt agonist Rspo2 has an established role in skeletal development, and here we 
present its significant role in osteoblasts in postnatal bone. Canonical Wnt signaling is one of the 
most studied pathways in bone due to its osteoanabolic effects through both enhancement of 
osteoblastogenesis and modulation of osteoblasts in remodeling. The pathway was originally 
implicated when loss-of-function mutations in Lrp5 were found to cause osteoporosis 
pseudoglioma syndrome, and a substantial body of research has been generated since this 
original finding (Gong et al., 2001; Monroe et al., 2012). In fact, the first Wnt-related therapeutic 
for osteoporosis is slated to gain FDA approval this year. Despite this great progress, the precise 
control of osteoblastogenesis and bone accrual mediated by Wnts is still largely unknown, with 
different ligands and different levels of signaling activity leading to unexpected and opposing 
effects. Furthermore, while there are many studied pathway inhibitors, there have few positive 
co-modulators of the pathway identified, making the R-spondins unique in their action. 
 Considering the positive regulation of the canonical Wnt pathway by the R-spondins and 
the established role of Rspo2 in skeletal development, we hypothesized that it may also have a 
positive regulatory role in osteoblastogenesis and bone accrual. Previous findings from our 
laboratory revealed that overexpression of Rspo2 in pre-osteoblasts enhanced 
osteoblastogenesis and mineralization (Friedman et al., 2009). Here, I utilized limb bud 
progenitor cells from Rspo2 knockout mice to assess in vitro osteoblastogenesis in Rspo2-null 
cells. However, the perinatal lethality of the global Rspo2-knockout mouse model precluded the 
study of Rspo2 in postnatal bone in vivo. To address this, I created a novel conditional Rspo2-
knockout mouse, and specifically disrupted the Rspo2 expression in osteoblasts via expression 
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of Cre-recombinase driven by the Osteocalcin promoter. This is the first report of the autocrine 
action of Rspo2 in osteoblasts. 
 Here, we show that Rspo2 deficiency causes defects in osteoblastogenesis, 
mineralization, and bone accrual. Rspo2-null osteoblasts undergo less mineralization than wild-
type cells, though their levels of ALP staining are similar. These Rspo2-null cells also have 
decreased expression of Osterix and Osteocalcin compared to wild-type cells, though levels of 
Runx2 and BSP are unaffected. This phenotype can be rescued by the addition of recombinant 
RSPO2 to the media. Altogether, Rspo2-null osteoblasts do have the ability to mineralize, as 
seen by Alizarin red S staining, and do so progressively over time. However, this mineralization is 
defective and never reaches wild-type levels. 
 Rspo2-deficiency in osteoblasts in vivo also leads to a phenotype of decreased 
mineralization. This was investigated through the development of a novel conditional mouse 
model of Rspo2 knockout. When mice with loxP sites floxing exons 4 and 5, are crossed to the 
pan-expressing Cre mouse, EIIa-Cre, for whole-body recombination, the offspring recapitulate 
the limb malformation phenotype and perinatal lethality phenotypes of the global Rspo2-
knockout. These mice were also crossed with Osteocalcin-Cre mice for specific recombination in 
the osteoblasts. Mice with Rspo2-deficient osteoblasts are smaller than their littermates, by 
both weight and crown-rump length. At 1, 3, and 6 months of age, their femurs are significantly 
shorter than their wild-type littermates. At all three timepoints investigated, these mice have 
decreased trabecular bone volume fraction, characterized by thinner trabeculae. At the 1 month 
timepoint there are also fewer trabeculae. Cortical bone is reduced in mice with Rspo2-deficient 
osteoblasts at 3 months, and the bones show reduced mechanical strength in bending. Non-
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statistically significant geometric differences persist at 6 months of age, and the changes are 
reflected in a continued reduction in mechanical strength of the Rspo2-deficient mice.  
Histomorphometric analysis revealed differences in bone volume fraction and 
trabecular thickness at 1 month of age similar to the findings with microCT. Additionally, these 
Ocn-Cre+Rspo2f/f mice have a decreased bone formation rate (BFR). This decreased BFR 
corresponds to a decreased mineral apposition rate, as the mineralizing surface ratio is not 
altered in the mice with Rspo2-deficient osteoblasts. When BM-MSC are harvested from these 
mice and stimulated to undergo osteoblastogenesis in vitro, they produce less mineral but have 
similar ALP staining. Additionally, when the progenitor cell population in the marrow is 
measured via CFU-F analysis, these mice have decreased total numbers and ALP-positive 
fraction of colonies produced. Altogether, these studies show that Rspo2 is critical for normal 
osteoblastogenesis and mineralization, and that when this deficiency occurs in vivo, there is a 
decreased bone formation rate that results in a decrease in total bone. 
 
3.2 DISCUSSION 
The role of R-spondin-2 in osteoblastogenesis of limb bud mesenchymal progenitor cells 
The differentiation and function of osteoblasts is critical to the formation and 
maintenance of bone, as discussed in Chapter One. Alterations in osteoblast and osteoclast 
activities disrupts remodeling homeostasis, causing alterations in bone mass and structure such 
as osteoporosis. Determining methods in which osteoblasts and osteoclasts can be modulated 
to re-establish this balance, or even shifting the balance in the favor of osteoblast-mediated re-
building of bone, is critical for the development of novel therapeutics for conditions of low bone 
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mass. Fundamental to this is an understanding of the signaling pathways and key factors 
involved in osteoblast differentiation and function.  
 Canonical Wnt signaling has been established as a positive regulator of both 
osteoblastogenesis and osteoblast activity (Monroe et al., 2012). Furthermore, R-spondins have 
been identified as agonists of Wnt signaling, and our laboratory previously showed that 
enhanced Rspo2 expression in pre-osteoblasts increased their mineralization in vitro (Friedman 
et al., 2009). In Chapter Two, we utilized limb bud mesenchymal progenitor cells from Rspo2-
knockout mice to address the question of the requirement of Rspo2 for osteoblastogenesis and 
mineralization. Given that R-Spondins are thought to enhance Wnt signaling by increasing the 
Wnt co-receptors at the cell surface, we hypothesized that some signaling would still occur in 
these cells, and thus they would still mineralize to some extent, albeit less efficiently than wild-
type cells. The Rspo2-null mesenchymal progenitor cells (MPC) had decreased mineralization at 
all timepoints assessed, confirming this hypothesis. Their ALP staining was similar to that of 
wild-type cells though, suggesting that early osteoblastogenesis may not be altered with Rspo2-
deficiency.  
 The multi-step process of the production of bone matrix may provide some insight into 
potential defects caused by Rspo2-deficiency during osteoblastogenesis. Initially, there is 
deposition of organic extracellular matrix, which consists primarily of type-I collagen, 
proteoglycans (including decorin and biglycan), and some non-collagen proteins such as 
osteocalcin, osteonectin, bone sialoprotein, and osteopontin. Next, mineralization occurs near 
the ends of aligned collagen fibrils.  Mineralization occurs in two stages: a vesicular stage and a 
fibrillar stage. During the vesicular stage, ALP releases inorganic phosphate from phosphate-
containing compounds in the vesicles. Additionally, proteoglycans in the matrix are degraded, 
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releasing calcium, which is transported into the vesicles through annexin channels. The 
concentrated calcium and phosphate ions, coordinated with other proteins and phospholipids, 
then nucleate and form hydroxyapatite crystals, which then grow and eventually rupture the 
vesicle and thus beginning the fibrillar stage (Clarke, 2008; Florencio-Silva et al., 2015). Given 
the normal ALP levels in Rspo2-deficient osteoblasts, along with the decreased mineralization, it 
is likely that another component of the mineralization pathway is disrupted. It is possible that 
this could be a defect in the deposition of type 1 collagen, leading to decreased sites of initial 
mineral nucleation. As well, alterations in the calcium- and phosphate- binding proteins or 
components of the nucleation complex in the vesicles could lead to decreased mineralization. 
Additionally, alterations in the annexin channels could lead to decrease calcium concentration in 
the vesicular microenvironment, resulting in decreased hydroxyapatite crystal nucleation. 
In order to mineralize, the MPC require an osteogenic growth factor. Typically, we use 
recombinant BMP6 for this purpose, but since R-spondins are known to stimulate both 
canonical and noncanonical signaling, it is important to consider how canonical and 
noncanonical signaling may affect the Rspo2-null MPC osteoblasts differentially. Wnt ligands 
Wnt3a and Wnt5a were used as growth factors to stimulate osteoblastogenesis in the MPC. 
While Wnt3a is an established canonical Wnt ligand, Wnt5a is commonly described as a 
noncanonical Wnt ligand, though it is known that the specificity for stimulation of one specific 
Wnt signaling pathway is not as strong as was once assumed. Although ALP staining was still 
similar in WT and Rspo2-null MPC treated with BMP6, Rspo2-null MPC treated with Wnt3a or 
Wnt5a had increased ALP staining compared to WT cells in the same conditions (Figure 3.1). 
Moreover, the ALP staining resulting from Wnt3a vs Wnt5a was similar within the same cell line. 
However, similar to stimulation with BMP6, Rspo2-null MPC had decreased levels of 
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mineralization compared to WT cells when stimulated with either Wnt ligand (data not shown). 
This discordance between these markers of two stages of osteoblastogenesis in the Rspo2-null 
cells is intriguing. Since ALP expression does decrease as osteoblastogenesis progresses in some 
cells, it is possible that this data is reflective of the Rspo2-null cells being retarded in their 
progression through osteoblastogenesis. However, these cells had increased staining compared 
to the wild-type cells at both 5 and 7 days. It is therefore more likely that these cells have 
decreased overall Wnt signaling due to the lack of Rspo2, and are not maintained in the 
progenitor cell state as efficiently, thus causing them to initiate osteoblastogenesis. Wnt 
signaling is also involved in downstream stages of differentiation to mature osteoblasts, and this 
is also likely hindered, causing the decreased mineralization observed. 
Another role established for canonical Wnt signaling in MPC is the concurrent inhibition 
of adipogenic cell fates and promotion towards the osteogenic fate. In contrast, noncanonical 
Wnt signaling is reported to increase adipogenesis. Moreover, the reciprocal relationship 
between adipogenesis and osteogenesis is commonly cited, mirroring the frequent reciprocal 
relationship between canonical and noncanonical Wnt signaling (Keats et al., 2014). Given this, 
and the phenotype of decreased osteogenesis that we established, we hypothesized that Rspo2-
null MPC would undergo significantly more adipogenesis than WT MPC. However, when 
stimulated to undergo adipogenesis, Rspo2-null MPC produced significantly less lipid than WT 
MPC, as seen by quantification of Oil Red O staining of cells (Figure 3.2). The puzzling lack of the 
reciprocal relationship here is likely due to one of two scenarios: i) cells are maintained in a 
progenitor cell state, or ii) differentiation is incomplete. When considering this data with the 
increased ALP staining observed with stimulation by Wnt ligands, it seems most likely that 
Rspo2-deficient cells are perhaps ‘stalled’ in osteoblastogenesis. It is possible that they are even 
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more stimulated to undergo osteoblastogenesis, rather than adipogenesis, given that they show 
both reductions in Oil Red O staining and increases in ALP staining. In this scenario, as 
mentioned above, it is likely that the decrease in Wnt signaling results in a lack of maintenance 
of the progenitor cell population. 
We also measured the relative osteogenic gene expression profiles of the Rspo2-null 
MPC compared to the WT MPC. The master regulator of osteoblastogenesis is reported to be 
the transcription factor, Runx2. Without expression of Runx2, no bone is formed (Otto et al., 
1997). Both the Rspo2-null and WT MPC showed induction of Runx2 with stimulation of 
osteoblastogenesis in vitro, with similar levels of expression. It could be expected that, given the 
above findings, expression of Runx2 would be higher in the Rspo2-null cells. However, there was 
not a difference observed here at the gene expression level.  A possible explanation for this is 
that Runx2 is known to be post-transcriptionally regulated, so Runx2 levels could be enhanced 
without changes in gene expression.    
The next major transcriptional regulator of osteoblastogenesis is the transcription 
factor, Osterix. In Osx-null mice, no bone matrix is deposited via endochondral or 
intramembranous ossification, though the hypertrophic cartilage is calcified in contrast to the 
Runx2-null mice. The Rspo2-null MPC show reduced expression of Osx at all timepoints 
compared to the WT MPC. Given this, it is somewhat surprising that these Rspo2-deficient cells 
are able to mineralize in vitro, as Osx-null MPC do not mineralize in culture (Nishimura et al., 
2012). Interestingly though, the Rspo2-null MPC go on to express down-stream osteogenic 
genes, such as Osteocalcin (initially reduced, as mentioned in Chapter 2) and BSP. This suggests 
that either the very low levels of Osx expression are sufficient to induce the expression of these 
downstream genes, or that there is a parallel pathway leading to their induction. However, this 
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downstream gene expression does provide an explanation for how the cells are able to 
eventually mineralize in culture. Many of the osteogenic genes contain Runx2- binding sites in 
their promoters, which are reported to work in concert with Osx for gene expression; however, 
it is possible that other factors are also able to serve this role, such as other Sp-family 
transcription factors (Thirunavukkarasu et al., 2002; Zhang et al., 2010). Moreover, consistent 
with the gene expression pattern of Rspo2 null cells, is the osteogenic gene expression seen in 
Lrp5- and Lrp6-null osteoblasts. These cells have reduced levels of Osx expression, but maintain 
normal levels of several downstream osteogenic genes (Riddle et al., 2013). Since R-spondins are 
known to inhibit LRP internalization by RNF43/ZNRF3, it is consistent that Rspo2-null and Lrp5/6 
null cells would have similar gene expression profiles. 
 The discordance between the osteogenic phenotypes of models of disruptions of 
osteogenic genes (such as Osterix) with our Rspo2 conditional knockout model invites the 
question of what other pathways, other than traditional beta-catenin signaling, may be involved 
in modulating the alternative osteogenic pathways. Given that R-spondins are known to 
modulate both canonical and noncanonical Wnt signaling, the noncanonical pathway is one 
likely potential alternative pathway. The furin domains of R-spondin are known to activate 
canonical Wnt signaling, while several reports have indicated that the TSR-1 domain activates 
noncanonical Wnt signaling (Kim et al., 2008; Ohkawara et al., 2011). To investigate this further, 
we generated domain-deletion constructs of Rspo2 for viral expression in MPC and analysis of 
osteogenesis (Figure 3.3). Initial findings show that full-length Rspo2 (WT) does not enhance 
mineralization in WT MPC compared to cells transduced with a control virus containing mCherry 
(mCh), similar to the treatment of WT MPC with recombinant RSPO2 in Chapter 2. However, full-
length Rspo2 does increase the mineralization of Rspo2-null MPC. Rspo2 lacking the furin 
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domains (dFur) and Rspo2 lacking the TSR-1 domain (dTSR) both increase mineralization in WT 
and Rspo2-null MPC. However, Rspo2 lacking the region corresponding to exons 4 and 5 (dEx4-
5, as in the conditional knockout model), appears to result in inhibition of mineralization in the 
WT MPC while increasing mineralization in Rspo2-null MPC (Figure 3.4). These data suggest that 
the furin and TSR domains may be acting in direct opposition to one another, as removal of 
either results in increased mineralization. The removal of one of the furin domains and the TSR-
1 domain, as in dEx4-5, is more complex and likely involves interaction with endogenous full-
length Rspo2 given the opposite effects in WT versus Rspo2-null MPC. If the domains are in fact 
working in opposition to one another, this may be consistent with the Furin domain enhancing 
canonical and the TSR enhancing noncanonical Wnt signaling. However, if that is the case, both 
canonical and noncanonical signaling would have to enhance osteoblastogenesis and 
mineralization, while also inhibiting the alternative type of Wnt signaling.  
 The role of non-canonical Wnt signaling in osteoblasts and bone biology remains poorly 
understood. As discussed in the previous chapters, a significant body of research supports that 
canonical Wnt signaling enhances osteoblastogenesis, though level of signaling through the 
pathway at various points in differentiation do not always produce a linear response. The data 
regarding the effects of noncanonical Wnt signaling are more variable. Explanations for this 
variability include: i) Wnt ligands are not as specific for canonical versus noncanonical as they 
were originally hypothesized, ii) there are many noncanonical signaling pathways in contrast to 
the singular canonical Wnt signaling pathway, and iii) due to the lack of pathway specific tools, it 
becomes more difficult to manipulate non-canonical signaling. To investigate this in our hands, 
we added small molecule inhibitors and activators of canonical Wnt/beta-catenin and 
noncanonical Wnt/PCP signaling in the media of differentiating cells. Though we had initially 
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hoped to do this in our Rspo2-null MPC, these cells proved too sensitive to survive functional 
concentrations of the small molecules. However, we were able to test these constructs in 
MC3T3-E1 pre-osteoblast cells. We found that lithium chloride (LiCl, a canonical Wnt signaling 
agonist) did not cause noticeable changes in mineralization and ALP staining, as has been seen in 
MC3T3-E1 cells previously. However, JNK-IN-8 (JI8, a Wnt/PCP signaling antagonist) increased 
mineralization, while pyrvinium (Pyr, a canonical Wnt signaling antagonist) and anisomycin (Ani, 
a Wnt/PCP signaling agonist) decreased mineralization and ALP staining in these cells (Figure 
3.5). These data are consistent with canonical Wnt signaling supporting enhanced 
osteoblastogenesis and noncanonical Wnt/PCP signaling inhibiting osteoblastogenesis. While 
this is somewhat discordant with the preliminary Rspo2 domain deletion data above, it does 
support much of the current literature, and it is possible that the TSR-1 domain is functioning 
through a different noncanonical pathway, or even a different signaling pathway altogether. 
 Overall, our data support the role of Rspo2 as a potentiator of osteoblastogenesis and 
define its role as necessary for normal osteoblastogenesis. Furthermore, the osteogenesis 
defects of Rspo2-null MPC are most similar to the Lrp5- and Lrp6-null MPC, which is consistent 
with their currently accepted interactions in modulation of canonical Wnt signaling. 
 
R-Spondin-2 deficiency in osteoblasts causes defective mineralization and decreased bone  
 While it is important to investigate osteoblastogenesis in vitro, it is also fundamental to 
examine osteoblastogenesis and osteoblast function in vivo. However, the global Rspo2ftl 
knockout mouse is perinatal lethal, precluding the study of postnatal bone. These mice do form 
bone in utero, unlike the Runx2- and Osx-knockout mice, but also have skeletogenesis defects 
resulting from altered signaling at the apical ectodermal ridge (AER) of the developing limbs 
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(Bell et al., 2003; Bell et al., 2008). Limb histology of embryonic Rspo2-deficient mice revealed 
differences in the zones of endochondral ossification consistent with the published work on 
Rspo2 disruption effects on the growth plate, but did not reveal further information regarding 
mature bone (data not shown) (Takegami et al., 2016). To circumvent the problems of perinatal 
lethality in complete Rspo2-knockouts, we created a novel conditional Rspo2-knockout model. 
The model uses the Cre-Lox recombination system, with loxP sites inserted 5’ and 3’ of exons 4 
and 5 of Rspo2. These exons correspond to one of the furin domains and the TSR-1 domain of 
Rspo2, which should produce a nonfunctional protein since it has been reported that both furin 
domains are needed in order to potentiate canonical Wnt signaling. This atypical targeting 
scheme was used because: i) the exons of Rspo2 are all in frame, ii) there is insufficient 
information about the endogenous Rspo2 promoter for targeting disruption of transcription, 
and iii) very large introns precluded targeting a larger region with homologous recombination. 
To confirm that this produced a non-functional Rspo2, this model was crossed to the EIIa-Cre 
mouse model for whole-body recombination with verified expression in bone. As reported in 
Chapter 2, homozygous targeted mice that were Cre-positive were all affected by skeletogenesis 
defects reminiscent of those seen in the global Rspo2ftl model. On average, the defects were less 
severe than the Rspo2ftl mouse, but this is to be expected in a Lox-Cre model as recombination is 
not 100% efficient.  
 We then crossed our new conditional Rspo2-knockout model to the Ocn-Cre model for 
specific Rspo2 knockout in osteoblasts, and we identified a mineralization defect that results in 
decreased bone mass. Interestingly, the model is most osteopenic at 3 months of age, with 
significantly less trabecular and cortical bone at this timepoint. At 6 months, the cortical bone 
geometry is no longer significantly different from WT mice and the trabecular bone differences 
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are attenuated, but mechanical function (bending strength) remains significantly decreased. In 
addition, it can be assumed, given the timing of Ocn expression, that the mice are similar until 
close to birth. Thus, over the first 3 months, the period of maximal bone accrual, the Rspo2-
knockout mice have increasingly lower bone mass compared to WT littermates, and sometime 
after this point, this difference begins to attenuate. 3 months of age is known to correspond to 
the peak trabecular bone mass in mice, following a period where bone formation exceeds bone 
resorption; therefore, defects in bone formation may be particularly evident during this time. 
The lack of progressive osteopenia, and indeed an attenuating phenotype, suggests that bone 
resorption may be concurrently decreased. This is supported by the decreased TRAP staining 
seen in this model, and could be due to decreased RANK ligand or increased osteoprotegerin 
produced by the defective osteoblasts. This could be particularly relevant for the goal of utilizing 
R-spondins or their receptors as a potential therapeutic target, as one would expect increased 
bone formation to be coupled with increased bone resorption.  
 In the osteoblast-specific Rspo2-knockout, there is a more significant reduction in 
trabecular bone mass than cortical bone mass. Though this is somewhat surprising, it has also 
been reported with other alterations of Wnt signaling in mouse models. For instance, the 
Wnt10b alterations and treatment with LiCl result in changes only in the trabecular bone 
(Bennett et al., 2005; Clément-Lacroix et al., 2005; Bennett et al., 2007). Clearly, regulation of 
cortical and trabecular bone mass can be influenced independently and/or variably by the same 
factors. This can be at least partially attributed to trabecular surfaces being subject to 
remodeling, while periosteal surfaces primarily undergo modeling (Sims and Martin, 2014). It 
may also reflect variable canonical Wnt responsiveness of cells forming cortical bone relative to 
those forming trabecular bone. 
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 In this Rspo2-knockout model, the primary cause of decreased bone mass appears to be 
defective osteoblasts that are unable to create bone matrix normally. This results in a decreased 
mineral apposition rate on the trabeculae, and thus thinner trabeculae. The fraction of the bone 
surface that is mineralizing, and the number of osteoblasts per bone surface, are not different 
from the WT mice. This further confirms that there is a lack of appropriate matrix deposition 
and mineralization, ultimately resulting in decreased bone formation rate and bone mass. 
Interestingly, while there appear to be adequate numbers of osteoblasts, when the progenitor 
population of the bone marrow of these mice are measured, there is a reduction in the total 
progenitor population, as well as a reduction in the percentage that are osteoprogenitors. While 
this does not appear to be the mechanism of decreased bone mass in this model, it may cause a 
more severe phenotype if these mice were ovarectomized or sustained fractures (Hadjiargyrou 
and O'Keefe, 2014). 
3.3 LIMITATIONS AND FUTURE DIRECTIONS 
Limitations 
As mentioned above, loxP sites were inserted around exons 4 and 5 of Rspo2. This atypical 
targeting strategy results in the deletion of one of the furin domains and the TSR-1 domain. 
Despite out observations, the signaling sequence, first furin domain, and C-terminus are intact 
and could theoretically produce a protein product. However, western blot analysis with an 
antibody directed at the C-terminus showed a strong reduction in protein expression. Further 
studies measuring mRNA fragments from either the N- or C-terminus could further delineate if 
any product is made. Given the decreased detection of the C-terminus by western blot and the 
recapitulation of the global knockout when the model is crossed to a pan-expressing Cre, this is 
likely a minimal limitation of the study. 
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 In this study, we utilized the Ocn-Cre recombinase mouse model for specific 
recombination in the osteoblasts. This is not an inducible Cre, and Ocn expression is established 
to begin at approximately E17 in the mouse. This means that part of the phenotype identified in 
these mice could be due to late prenatal and postnatal development. These prenatal changes 
may cause skeletal developmental alterations that are the primary cause of the skeletal 
phenotypic changes identified at later timepoints rather than due to true osteoblastic 
deficiencies. The use of an inducible osteoblast-specific cre, such as Ocn-Cre-ERT2, would 
eliminate these potential embryonic developmental effects for more precise identification of 
postnatal bone remodeling changes. However, we measured the skeletal phenotypes of these 
mice at 3 timepoints, correlating to a juvenile age, a young adult with peak trabecular bone 
mass, and a mature adult. Evaluating not merely one individual timepoint, but the changes 
across significant murine life stages allows for interpretation of the adult remodeling phenotype, 
along with any phenotype that may be more purely developmental. Furthermore, Ocn-Cre is not 
exclusively expressed in osteoblasts. It is also expressed in hypertrophic chondrocytes, and 
anecdotal reports have purported expression in the brain (Personal Communication, Warman). 
While there is a decrease in the femur length at all ages assessed in the targeted mice, their 
growth plates appear normal, unlike the growth plates of global Rspo2-knockout mice. Likewise, 
other disruptions of Wnt signaling result in shortened bones. 
 In this study, we primarily compared Ocn-Cre+ and Ocn-Cre- mice, both with a Rspo2f/f 
genotype. Initially, we included mice that were wild-type and heterozygous at the Rspo2 locus 
as well, but concentrated on the homozygous targeted mice after preliminary investigations. 
The Ocn-Cre-Rspo2f/f mice were the smallest of the control mice, consistent with previous 
mouse model studies involving genetic manipulation. Given this, these mice would not 
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overestimate the differences between wild-type and targeted mice, and in fact may 
underestimate these differences. These mice are also the closest in background to the targeted 
mice, which is why they were selected for our complete studies. It is possible that the floxed 
allele alone could lead to differences in bone regulation that we did not control for. Since these 
were not seen in preliminary investigations, this limitation in our studies is likely minimal. 
 The mouse as a model for human bone is imperfect. Mice do not have Haversian 
systems in their cortical bone, thus they do not remodel their cortical bone in the same way that 
humans do. However, they do remodel their trabecular bone similarly to humans, albeit at a 
higher rate due to their higher overall metabolism. Additionally, mice do not have closure of 
their growth plates with the associated fusion of the metaphysis and epiphysis. However, 
growth slows significantly with sexual maturity, and in C57Bl/6 mice specifically, no further 
femoral lengthening has been observed past 6 months of age (Jilka, 2013). If Rspo2 was thought 
to play an important role in Haversian remodeling, another animal model would need to be 
utilized. There is a known mRNA-stabilizing mutation in Rspo2 in dogs that results in external 
changes visualized in their coats, but their bones have not yet been investigated (Cadieu et al., 
2009). Given the easily identifiable external features of dogs with the mutation due to coat 
changes, and the extensively established pedigrees of purebred dogs, this would be an excellent 
model to identify cortical bone mass alterations in the context of alterations in Rspo2.   
 In this dissertation, only long bones were analyzed. Further investigation into the axial 
skeleton is warranted given the changes identified in the appendicular skeleton. Similarly, 
alterations in vertebral bone mass have been identified with alterations in Wnt signaling. 
Moreover, decreased bone mass in the vertebrae and resultant fractures are common in 
osteoporosis, making bone loss in this region particularly clinically significant. Our studies 
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establish changes in bone mass regulation in a mouse model, and these could be extended to 
the axial skeleton as well. 
 Finally, in our investigations of both MPC and BM-MSC, we are culturing a mixed 
population of cells. Though these populations are primarily progenitor and pre-osteoblast cells, 
there are a small percentage of cells that are of other types and could contribute to the 
phenotypes measured. Isolation of cells of both types is commonly used in many labs, though, 
so comparisons can be easily made. Purified populations of cells could be isolated based on cell-
surface markers, but there is little consensus regarding which markers should be used for 
sorting MSC of mice. For the purposes of our studies, these populations of cells were considered 
of sufficiently pure quality, and we did not observe differences between the cells of any 
genotype via microscopy. Importantly, two distinct cell types deficient in Rspo2, embryonic limb 
bud and marrow-derived MSC from adults, showed a similar phenotype.  
 
Future Directions 
Elucidate the structure-function mechanism of Rspo2 activity 
 Our data show that Rspo2 is critical for normal osteoblastogenesis and bone accrual, 
and that addition of Rspo2 enhances these processes. We have preliminary data suggesting that 
the modular structure of Rspo2 may allow it to signal through multiple pathways, and that these 
functions may oppose each other during osteoblastogenesis. Continued investigation utilizing 
the domain-deletion mutants into the osteogenic gene expression and activity of potential 
signaling pathways will further elucidate this. Specifically, crossing this mouse line to a Wnt-
reporter mouse line such as the TOPGAL mouse line, would elucidate changes in canonical Wnt 
signaling in mice with Rspo2-deficient osteoblasts. In vitro, this could also be investigated 
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transfecting Rspo2-deficient osteoblasts with a luciferase Wnt reporter such as TOPFlash and 
comparing light emission with WT osteoblasts. Increased understanding of Rspo2 mechanisms 
of action could potentially lead to greater enhancement of osteoblastogenesis and bone accrual, 
as well as provide a way to fine-tune the level of osteogenic stimulation to different levels as 
clinically appropriate. 
 
Redundancy of R-spondins 
 The R-Spondins are a family of four similar molecules, as discussed in Chapter one. It is 
very likely that there is some redundancy between them. Creating compound knockouts, as well 
as measuring the expression of the other R-spondins in the context of knockdown of one family 
member are potential options for how this investigation could be pursued.  So far it has been 
reported that conditional deletion of Rspo3 in developing limb mesenchyme of Rspo2 
heterozygous mice increases the skeletogenesis defects (McGee-Lawrence et al., 2011).  
 
Osteoblast-osteoclast coupling with Rspo2-deficient osteoblasts 
 Osteoblast-osteoclast coupling in vivo is well established, and is one of the primary 
mechanisms of regulation of bone mass. Here, we show that when Rspo2 is disrupted in 
osteoblasts, TRAP staining of osteoclasts decreases. This suggests that stimulation of osteoclasts 
by these defective osteoblasts also decreases. It would be informative to measure RANKL and 
osteoprotegerin expression in osteoblasts, as well as to study osteoclasts cultured in 
conditioned media from Rspo2-null osteoblasts. This coupling is an important consideration 
when selecting targets and designing novel therapeutics for the regulation of bone mass. 
 
73 
 
Rspo2-deficiency in models of low bone mass and regeneration 
 One of the most important next studies will be to challenge the mice with Rspo2 
disruption in their osteoblasts. This can be done via ovariectomy or administration of 
corticosteroid, which result in loss of bone mass in mice. Disuse models via tail suspension can 
also be used for this purpose. Fracture studies could also be performed to investigate the 
regenerative ability of Rspo2-null osteoblasts. Of course, the reciprocal experiments of 
challenging the models using one of these mechanisms and adding Rspo2 would also be very 
informative regarding Rspo2’s potential to aid in reducing osteoporotic bone loss and enhancing 
fracture healing.  
 
3.4 CONCLUDING REMARKS 
 This dissertation is the first report of an Rspo2 conditional knockout mouse model, as 
well as being the first to investigate Rspo2 in postnatal bone. Specifically, mice with Rspo2-null 
osteoblasts were shown to have decreased bone mass due to defective osteoblasts. These 
osteoblasts lead to a decreased bone formation rate, thus causing the mice to have thinner 
trabeculae and reduced overall bone volume fraction. Mice with Rspo2-null osteoblasts also had 
fewer progenitor cells in their bone marrow. These findings were corroborated by decreased 
osteoblastogenesis and mineralization of Rspo2-null mesenchymal progenitor cells in vitro.  
These data establish Rspo2 as a critical regulator of bone mass for the first time. Development 
of this new mouse model provides the foundational steps for evaluation of Rspo2 function in 
osteoblasts during bone loss and fracture, and ultimately in establishing novel therapeutics for 
regulating bone mass based on the Wnt agonist Rspo2.  
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Figure 3.1. Alkaline Phosphatase staining of Rspo2-null MPC undergoing Wnt-stimulated 
osteoblastogenesis. Cells were treated with 100ng/mL Wnt3a, 100ng/mL Wnt5a, or 2.5nM 
BMP6. Staining at 7 days post-osteogenic induction. MM = Maintenance Media; OGM = 
Osteogenic Media.  
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Figure 3.2. Rspo2-null MPC have reduced adipogenesis in vitro. Quantification of Oil Red O 
staining of wells 7 days post induction of adipogenesis. MM = Maintenance Media, AGM = 
Adipogenic Media. *p<0.05, **p<0.01 by 2-way ANOVA with Tukey’s corrections for multiple 
comparisons. 
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Figure 3.3. Rspo2 domain-deletion constructs. Domain-deletion constructs designed to test the 
structure-function relationship of Rspo2. dFur lacks both Furin repeat domains. dTSR lacks the 
Thrombospondin type 1 repeat domain. dEx4-5 lacks the region corresponding to Exons 4 and 5, 
similar to the conditional Rspo2-knockout mouse model. 
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Figure 3.4. Osteogenesis of MPC with Rspo2 domain-deletion constructs. Alizarin red S staining 
of MPC 10 days post-induction of osteogenesis. Cells were transduced with lentivirus according 
to the indicated labels: mCh=mCherry, WT=full-length Rspo2, dFur=Rspo2 lacking the furin 
domains, dTSR=Rspo2 lacking the TSR-1 domain, dEx4-5=Rspo2 lacking the region corresponding 
to exons 4 and 5. MM = Maintenance Media, OGM = Osteogenic Media. 
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Figure 3.5. Osteogenesis of MC3T3-E1 cells treated with activators and inhibitors of Wnt 
signaling. A. ALP staining of cells 5 days post induction of osteogenesis. B. Alizarin red S staining 
of mineralization of cells 10 days post induction of osteogenesis. MM = Maintenance Media, 
OGM = Osteogenic Media. UnT = Untreated, DMSO = vehicle control, LiCl = lithium chloride, Pyr 
= pyrvinium, Ani = Anisomycin, JI8 = JNK-Inhibitor-8. 
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